<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ONGLYZAÂ - saxagliptin hydrochlorideÂ tablet, film coatedÂ </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ONGLYZA safely and effectively. See full prescribing information for ONGLYZA.<br><br><br>ONGLYZA (saxagliptin) tablets
      <br>Initial U.S. Approval: 2009</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Indications and Usage<br>Â Â Â Â Â Important Limitations of Use <a href="#s1.2">(1.2)</a>Â Â Â Â Â 11/2011<br>Dosage and Administration<br>Â Â Â Â Â Recommended Dosing <a href="#s2.1">(2.1)</a>Â Â Â Â Â 12/2011<br>Â Â Â Â Â Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin <a href="#s2.4">(2.4)</a>Â Â Â Â Â 12/2011<br>Contraindications <a href="#s4">(4)</a>Â Â Â Â Â 11/2011<br>Warnings and Precautions<br>Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> <a href="#s5.1">(5.1)</a>Â Â Â Â Â 11/2011<br>Â Â Â Â Â Use with Medications Known to Cause <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> <a href="#s5.2">(5.2)</a>Â Â Â Â Â 12/2011<br>Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> <a href="#s5.3">(5.3)</a>Â Â Â Â Â 11/2011 </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">ONGLYZA is a dipeptidyl
peptidase-4 (DPP4) inhibitor indicated as an adjunct to diet and exercise to improve
glycemic control in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus in multiple clinical settings. <a href="#s1.1">(1.1</a>, <a href="#s14">14)</a> </p>
<p class="Highlighta"> Important
limitations of use:  </p>
<ul class="Disc">
<li>Should not be used for the treatment of type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus
or <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>. <a href="#s1.2">(1.2)</a>
</li>
<li>Has not been studied in patients with a history of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. <a href="#s1.2">(1.2, </a><a href="#s5.1">5.1)</a>
</li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>The recommended dose is 2.5 mg or 5 mg once daily taken regardless
of meals. <a href="#s2.1">(2.1)</a>
</li>
<li>2.5 mg daily is recommended for patients with moderate or severe
<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, or end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (CrCl â‰¤50 mL/min).  Assess renal
function before starting ONGLYZA and periodically thereafter. <a href="#s2.2">(2.2)</a>
</li>
<li>2.5 mg daily is recommended for patients also taking strong cytochrome
P450 3A4/5 (CYP3A4/5) inhibitors (e.g., ketoconazole). <a href="#s2.3">(2.3</a>,<a href="#s7.1"> 7.1)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>Tablets: 5 mg and 2.5 mg <a href="#s3">(3)</a>
</li></ul></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc"><li>History of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, exfoliative skin conditions) to ONGLYZA. <a href="#s4">(4)</a>
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>There have been postmarketing reports of <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span>. If <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> is suspected, promptly discontinue ONGLYZA. <a href="#s5.1">(5.1)</a>
</li>
<li>When used with an insulin secretagogue (e.g., sulfonylurea) or insulin, a lower
dose of the insulin secretagogue or insulin may be required to minimize the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. <a href="#s5.2">(5.2)</a>
</li>
<li>There have been postmarketing reports of serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> in patients treated with ONGLYZA such as <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, and exfoliative skin conditions. In such cases, promptly discontinue ONGLYZA, assess for other potential causes, institute appropriate monitoring and treatment, and initiate alternative treatment for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. <a href="#s5.3">(5.3</a>, <a href="#s6.2">6.2)</a>
</li>
<li>There have been no clinical studies establishing conclusive evidence
of macrovascular risk reduction with ONGLYZA or any other antidiabetic drug. <a href="#s5.4">(5.4)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul class="Disc">
<li>Adverse reactions reported in â‰¥5% of patients treated with ONGLYZA
and more commonly than in patients treated with placebo are: upper respiratory
tract <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. <a href="#s6.1">(6.1)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span> was reported more commonly in patients treated
with the combination of ONGLYZA and a thiazolidinedione (TZD) than in patients
treated with the combination of placebo and TZD. <a href="#s6.1">(6.1)</a>
</li>
<li>In the add-on to sulfonylurea and add-on to insulin trials, confirmed <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was reported more commonly in patients treated with ONGLYZA compared to placebo. <a href="#s6.1">(6.1)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>-related events (e.g., <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>)
were reported more commonly in patients treated with ONGLYZA than in patients
treated with placebo. <a href="#s6.1">(6.1)</a>
</li>
</ul>
<p class="Highlighta">Â <br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers Squibb at 1-800-721-5072 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch</span></span> </p>
</div>
<div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc"><li>Coadministration with strong CYP3A4/5 inhibitors (e.g., ketoconazole)
significantly increases saxagliptin concentrations. Recommend limiting ONGLYZA
dose to 2.5 mg once daily. <a href="#s2.3">(2.3</a>, <a href="#s7.1">7.1)</a>
</li></ul></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>No adequate and well-controlled studies in pregnant women. <a href="#s8.1">(8.1)</a>
</li>
<li>Safety and effectiveness of ONGLYZA in pediatric patients below
the age of 18 have not been established. <a href="#s8.4">(8.4)</a>
</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div>
<div><div></div></div>
<div><div></div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 1/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1  INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Monotherapy and Combination Therapy</a></h2>
<h2><a href="#section-1.2" class="toc">1.2  Important Limitations of Use</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION </a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommended Dosing</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Strong CYP3A4/5 Inhibitors</a></h2>
<h2><a href="#section-2.4" class="toc"><span class="XmChange">2.4 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1  <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2  Use with Medications Known to Cause <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4  Macrovascular Outcomes</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2  Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Strong Inhibitors of CYP3A4/5 Enzymes</a></h2>
<h1><a href="#section-8" class="toc">8  USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Monotherapy</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Combination Therapy</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17  PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1  Instructions</a></h2>
<h2><a href="#section-15.2" class="toc">17.2  Laboratory Tests</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>1  INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Monotherapy and Combination Therapy</h2>
<p class="First">ONGLYZA is indicated as an adjunct
to diet and exercise to improve glycemic control in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>
mellitus in multiple clinical settings. [See <span class="Italics"><a href="#s14">Clinical Studies (14)</a></span>.]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2  Important Limitations of Use</h2>
<p class="First"> ONGLYZA should not be used for the treatment of type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus or <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>, as it would
not be effective in these settings.</p>
<p style="border-left:1px solid;"><span class="XmChange">ONGLYZA has not been studied in patients with a history of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. It is unknown whether patients with a history of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> are at an increased risk for the development of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> while using ONGLYZA. [See <span class="Italics"><a href="#s5.1">Warnings and Precautions (5.1)</a></span>.]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommended Dosing</h2>
<p class="First">The recommended dose of ONGLYZA is
2.5 mg or 5 mg once daily taken regardless of meals.</p>
<p style="border-left:1px solid;"><span class="XmChange">ONGLYZA tablets must not be split or cut.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No dosage adjustment for ONGLYZA
is recommended for patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance
[CrCl] &gt;50 mL/min).</p>
<p>The dose of ONGLYZA is 2.5 mg once
daily for patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, or with end-stage
<span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (ESRD) requiring hemodialysis (creatinine clearance [CrCl]Â â‰¤50Â mL/min)  [see <span class="Italics"><a href="#s12.3">Clinical Pharmacology (12.3)</a></span> and <span class="Italics"><a href="#s14.3">Clinical Studies (14.3)</a></span>].
ONGLYZA should be administered following hemodialysis. ONGLYZA has not been
studied in patients undergoing peritoneal dialysis.</p>
<p>Because
the dose of ONGLYZA should be limited to 2.5 mg  based upon renal function,
assessment of renal function is recommended prior to initiation of ONGLYZA
and periodically thereafter. Renal function can be estimated from serum creatinine
using the Cockcroft-Gault formula or Modification of Diet in <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span>
formula. [See <span class="Italics"><a href="#s12.3">Clinical Pharmacology (12.3)</a></span>.]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Strong CYP3A4/5 Inhibitors</h2>
<p class="First">The dose of ONGLYZA is 2.5 mg once daily
when coadministered with strong cytochrome P450 3A4/5 (CYP3A4/5) inhibitors
(e.g., ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole,
nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin). [See <span class="Italics"><a href="#s7.1">Drug Interactions (7.1)</a></span> and <span class="Italics"><a href="#s12.3">Clinical
Pharmacology (12.3)</a></span>.]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2.4"></a><a name="section-2.4"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">2.4 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">When ONGLYZA is used in combination with an insulin secretagogue (e.g., sulfonylurea) or with insulin, a lower dose of the insulin secretagogue or insulin may be required to minimize the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. [See <span class="Italics"><a href="#s5.1">Warnings and Precautions (5.1)</a></span>.]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s3.1"></a><a name="section-3.1"></a><p></p>
<ul class="Disc"><li>ONGLYZA (saxagliptin) 5 mg tablets are pink, biconvex, round, film-coated
tablets with â€œ5â€? printed on one side and â€œ4215â€? printed on the reverse side,
in blue ink.</li></ul>
<ul class="Disc"><li>	ONGLYZA (saxagliptin) 2.5 mg tablets are <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow to light yellow,
biconvex, round, film-coated tablets with â€œ2.5â€? printed on one side and â€œ4214â€?
printed on the reverse side, in blue ink.</li></ul>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange">History of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to ONGLYZA, such as <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, or exfoliative skin conditions. [See <span class="Italics"><a href="#s5.3">Warnings and Precautions (5.3)</a></span> and <span class="Italics"><a href="#s6.2">Adverse Reactions (6.2)</a></span>.]</span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1  <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">There have been postmarketing reports of <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span> in patients taking ONGLYZA. After initiation of ONGLYZA, patients should be observed carefully for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. If <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> is suspected, ONGLYZA should promptly be discontinued and appropriate management should be initiated. It is unknown whether patients with a history of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> are at increased risk for the development of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> while using ONGLYZA.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2  Use with Medications Known to Cause <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></h2>
<p class="First">When ONGLYZA was used in combination with a sulfonylurea or with insulin, medications known to cause <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, the incidence of confirmed <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was increased over that of placebo used in combination with a sulfonylurea or with insulin. [See <span class="Italics"><a href="#s6.1">Adverse Reactions (6.1)</a></span>.] Therefore, a lower dose of the insulin secretagogue or insulin may
be required to minimize the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> when used in combination with
ONGLYZA. [See <span class="Italics"><a href="#s2.4">Dosage and Administration (2.4)</a></span>.]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">There have been postmarketing reports of serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> in patients treated with ONGLYZA. These reactions include <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, and exfoliative skin conditions. Onset of these reactions occurred within the first 3 months after initiation of treatment with ONGLYZA, with some reports occurring after the first dose. If a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> is suspected, discontinue ONGLYZA, assess for other potential causes for the event, and institute alternative treatment for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. [See <span class="Italics"><a href="#s6.2">Adverse Reactions (6.2)</a></span>.]</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Use caution in a patient with a history of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> to another dipeptidyl peptidase-4 (DPP4) inhibitor because it is unknown whether such patients will be predisposed to <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> with ONGLYZA.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4  Macrovascular Outcomes</h2>
<p class="First">There have been no clinical studies establishing
conclusive evidence of macrovascular risk reduction with ONGLYZA or any other
antidiabetic drug.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted
under widely varying conditions, adverse reaction rates observed in the clinical
trials of a drug cannot be directly compared to rates in the clinical trials
of another drug and may not reflect the rates observed in practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.1.0.1"></a><a name="section-6.1.1"></a><p></p>
<h3>Monotherapy and Add-On Combination Therapy</h3>
<p class="First">In two placebo-controlled monotherapy
trials of 24-weeks duration, patients were treated with ONGLYZA 2.5 mg daily,
ONGLYZA 5 mg daily, and placebo. Three 24-week, placebo-controlled, add-on
combination therapy trials were also conducted: one with metformin, one with a
thiazolidinedione (pioglitazone or rosiglitazone), and one with glyburide.
In these three trials, patients were randomized to add-on therapy with ONGLYZA
2.5 mg daily, ONGLYZA 5 mg daily, or placebo. A saxagliptin 10 mg treatment
arm was included in one of the monotherapy trials and in the add-on combination
trial with metformin.</p>
<p>In a prespecified pooled analysis
of the 24-week data (regardless of glycemic rescue) from the two monotherapy
trials, the add-on to metformin trial, the add-on to thiazolidinedione (TZD)
trial, and the add-on to glyburide trial, the overall incidence of adverse
events in patients treated with ONGLYZA 2.5 mg and ONGLYZA 5 mg was similar
to placebo (72.0% and 72.2% versus 70.6%, respectively). Discontinuation of
therapy due to adverse events occurred in 2.2%, 3.3%, and 1.8% of patients
receiving ONGLYZA 2.5 mg, ONGLYZA 5 mg, and placebo, respectively. The most
common adverse events (reported in at least 2 patients treated with ONGLYZA
2.5 mg or at least 2 patients treated with ONGLYZA 5 mg) associated with premature
discontinuation of therapy included <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span> (0.1% and 0.5% versus 0%,
respectively), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (0.2% and 0.3% versus 0.3%), blood creatinine increased
(0.3% and 0% versus 0%), and <span class="product-label-link" type="condition" conceptid="4294804" conceptname="Creatine kinase">blood creatine phosphokinase</span> increased (0.1%
and 0.2% versus 0%). The adverse reactions in this pooled analysis reported
(regardless of investigator assessment of causality) in â‰¥5% of patients treated
with ONGLYZA 5 mg, and more commonly than in patients treated with placebo
are shown in Table 1.</p>
<a name="idecebceb-a794-4f99-8544-79a70d36bfc9"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 1: Adverse Reactions (Regardless of Investigator Assessment
of Causality) in Placebo-Controlled Trials* Reported in â‰¥5% of Patients Treated
with ONGLYZA 5 mg and More Commonly than in Patients Treated with Placebo</span></caption>
<colgroup>
<col width="33.3%">
<col width="33.3%">
<col width="33.4%">
</colgroup>
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule">Â </th>
<th class="Lrule Rrule Toprule" align="center" colspan="2"><span class="Bold">Number (%)
of Patients</span></th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule">Â </th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">ONGLYZA
5 mg<br>N=882</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Placebo<br>N=799</span></th>
</tr>
</thead>
<tfoot><tr class="First Last"><td class="Toprule" colspan="3">*Â Â The 5
placebo-controlled trials include two monotherapy trials and one add-on combination
therapy trial with each of the following: metformin, thiazolidinedione, or
glyburide. Table shows 24-week data regardless of glycemic rescue.</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">68 (7.7)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">61 (7.6)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">60 (6.8)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">49 (6.1)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">57 (6.5)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">47 (5.9)</td>
</tr>
</tbody>
</table>
<p>In patients treated with ONGLYZA 2.5 mg, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (6.5%)
was the only adverse reaction reported at a rate â‰¥5% and more commonly than
in patients treated with placebo.</p>
<p>In this pooled analysis,
adverse reactions that were reported in â‰¥2% of patients treated with ONGLYZA
2.5 mg or ONGLYZA 5 mg and â‰¥1% more frequently compared to placebo included:
<span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span> (2.9% and 2.6% versus 1.6%, respectively), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (2.4%
and 1.7% versus 0.5%), <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span> (1.9% and 2.3% versus 0.9%), and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>
(2.2% and 2.3% versus 1.3%).</p>
<p>In the add-on to TZD trial,
the incidence of <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> was higher for ONGLYZA 5 mg versus placebo
(8.1% and 4.3%, respectively). The incidence of <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> for ONGLYZA
2.5 mg was 3.1%. None of the reported adverse reactions of <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>
resulted in study drug discontinuation. Rates of <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> for ONGLYZA
2.5 mg and ONGLYZA 5 mg versus placebo were 3.6% and 2% versus 3% given as
monotherapy, 2.1% and 2.1% versus 2.2% given as add-on therapy to metformin,
and 2.4% and 1.2% versus 2.2% given as add-on therapy to glyburide.</p>
<p>The
incidence rate of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> was 1.0 and 0.6 per 100 patient-years, respectively,
for ONGLYZA (pooled analysis of 2.5 mg, 5 mg, and 10 mg) and placebo. The
incidence rate of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> events in patients who received ONGLYZA did not
increase over time. Causality has not been established and nonclinical studies
have not demonstrated adverse effects of saxagliptin on bone.</p>
<p>An
event of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, consistent with a diagnosis of idiopathic thrombocytopenic
<span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, was observed in the clinical program. The relationship of this event
to ONGLYZA is not known.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.1.1.1.1"></a><a name="section-6.1.1.1"></a><p></p>
<h4>Use in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h4>
<p class="First">ONGLYZA 2.5 mg was compared to placebo in a 12-week trial in 170 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and moderate or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (ESRD). The incidence of adverse events, including serious adverse events and discontinuations due to adverse events, was similar between ONGLYZA and placebo.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.1.1.1.2"></a><a name="section-6.1.1.2"></a><p></p>
<h4>Use in Combination with Insulin</h4>
<p class="First">In the add-on to insulin trial [see <span class="Italics"><a href="#s14.2">Clinical Studies (14.2)</a></span>], the incidence of adverse events, including serious adverse events and discontinuations due to adverse events, was similar between ONGLYZA and placebo, except for confirmed <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (see <span class="Bold"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></span> subsection).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.1.0.2"></a><a name="section-6.1.2"></a><p></p>
<h3>Adverse Reactions Associated with ONGLYZA Coadministered with Metformin in Treatment-Naive Patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></h3>
<p class="First">Table 2 shows the adverse reactions
reported (regardless of investigator assessment of causality) in â‰¥5% of patients
participating in an additional 24-week, active-controlled trial of coadministered
ONGLYZA and metformin in treatment-naive patients.</p>
<a name="i07cad84a-c670-437b-81a1-d88264f92c17"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 2: Initial Therapy with Combination of ONGLYZA and Metformin
in Treatment-Naive Patients: Adverse Reactions Reported (Regardless of Investigator
Assessment of Causality) in â‰¥5% of Patients Treated with Combination Therapy
of ONGLYZA 5 mg Plus Metformin (and More Commonly than in Patients Treated
with Metformin Alone)</span></caption>
<colgroup>
<col width="25%">
<col width="37.5%">
<col width="37.5%">
</colgroup>
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule">Â </th>
<th class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><span class="Bold">Number
(%) of Patients</span></th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule" align="center" valign="top">Â </th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">ONGLYZA
5 mg + Metformin*<br>N=320</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">Metformin*<br>N=328</span></th>
</tr>
</thead>
<tfoot><tr class="First Last"><td class="Toprule" colspan="3">*Â Â Metformin
was initiated at a starting dose of 500 mg daily and titrated up to a maximum
of 2000 mg daily.</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">24 (7.5)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">17 (5.2)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">22 (6.9)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">13 (4.0)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.1.0.3"></a><a name="section-6.1.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></h3>
<p class="First">Adverse reactions of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> were
based on all reports of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. A concurrent glucose measurement was
not required or was normal in some patients. Therefore, it is not possible to conclusively determine that all these reports reflect true <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
<p>In the add-on to glyburide study, the overall incidence of reported
<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was higher for ONGLYZA 2.5 mg and ONGLYZA 5 mg (13.3% and 14.6%)
versus placebo (10.1%). The incidence of confirmed <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in this study,
defined as symptoms of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> accompanied by a fingerstick glucose value
of â‰¤50 mg/dL, was 2.4% and 0.8% for ONGLYZA 2.5 mg and ONGLYZA 5 mg and 0.7%
for placebo [see <span class="Italics"><a href="#s5.2">Warnings and Precautions (5.2)</a></span>]. The incidence of reported <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> for ONGLYZA 2.5 mg and
ONGLYZA 5 mg versus placebo given as monotherapy was 4.0% and 5.6% versus
4.1%, respectively, 7.8% and 5.8% versus 5% given as add-on therapy to metformin,
and 4.1% and 2.7% versus 3.8% given as add-on therapy to TZD. The incidence
of reported <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was 3.4% in treatment-naive patients given ONGLYZA
5 mg plus metformin and 4.0% in patients given metformin alone.</p>
<p>In the active-controlled trial comparing add-on therapy with ONGLYZA 5 mg to glipizide in patients inadequately controlled on metformin alone, the incidence of reported <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was 3% (19 events in 13 patients) with ONGLYZA 5 mg versus 36.3% (750 events in 156 patients) with glipizide. Confirmed symptomatic <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (accompanying fingerstick blood glucose â‰¤50 mg/dL) was reported in none of the ONGLYZA-treated patients and in 35 glipizide-treated patients (8.1%) (p&lt;0.0001).</p>
<p>During 12 weeks of treatment in patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or ESRD, the overall incidence of reported <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was 20% among patients treated with ONGLYZA 2.5 mg and 22% among patients treated with placebo. Four ONGLYZA-treated patients (4.7%) and three placebo-treated patients (3.5%) reported at least one episode of confirmed symptomatic <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (accompanying fingerstick glucose â‰¤50 mg/dL).</p>
<p>In the add-on to insulin trial, the overall incidence of reported <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was 18.4% for ONGLYZA 5 mg and 19.9% for placebo. However, the incidence of confirmed symptomatic <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (accompanying fingerstick blood glucose â‰¤50 mg/dL) was higher with ONGLYZA 5 mg (5.3%) versus placebo (3.3%) [see <span class="Italics"><a href="#s5.2">Warnings and Precautions (5.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.0.1.4"></a><a name="section-6.1.4"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>-related events, such
as <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> in the 5-study pooled analysis up to Week 24
were reported in 1.5%, 1.5%, and 0.4% of patients who received ONGLYZA 2.5
mg, ONGLYZA 5 mg, and placebo, respectively.  None of these events in patients
who received ONGLYZA required hospitalization or were reported as life-threatening
by the investigators. One saxagliptin-treated patient in this pooled analysis
discontinued due to <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">generalized urticaria</span> and facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.0.1.7"></a><a name="section-6.1.5"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h3>
<p class="First">In the unblinded, controlled, clinical trial database for saxagliptin to date, there have been 6 (0.12%) reports of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> among the 4959 saxagliptin-treated patients (1.1 per 1000 patient-years) compared to no reports of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> among the 2868 comparator-treated patients. Two of these six cases were confirmed with laboratory testing. The remaining cases had limited information or had presumptive diagnoses of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>. None of the six cases occurred in the United States or in Western Europe. One case occurred in Canada in a patient originally from Indonesia who had recently visited Indonesia. The duration of treatment with saxagliptin until report of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> ranged from 144 to 929 days. Post-treatment lymphocyte counts were consistently within the reference range for four cases. One patient had <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span> prior to initiation of saxagliptin that remained stable throughout saxagliptin treatment. The final patient had an isolated lymphocyte count below normal approximately four months prior to the report of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>. There have been no spontaneous reports of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> associated with saxagliptin use. Causality has not been estimated and there are too few cases to date to determine whether <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> is related to saxagliptin use.</p>
<p>
There has been one case of a potential <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infection</span> in the unblinded, controlled clinical trial database to date in a saxagliptin-treated patient who developed suspected foodborne fatal <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">salmonella</span> <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> after approximately 600 days of saxagliptin therapy. There have been no spontaneous reports of <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> associated with saxagliptin use.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.0.1.5"></a><a name="section-6.1.6"></a><p></p>
<h3>Vital Signs</h3>
<p class="First">No clinically meaningful changes in vital
signs have been observed in patients treated with ONGLYZA.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="s6.1.0.6"></a><a name="section-6.1.7"></a><p></p>
<h3>Laboratory Tests</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.0.1.6.1"></a><a name="section-6.1.7.1"></a><p></p>
<h4>Absolute Lymphocyte Counts</h4>
<p class="First">There was a dose-related mean decrease
in absolute lymphocyte count observed with ONGLYZA. From a baseline mean absolute
lymphocyte count of approximately 2200 cells/microL, mean decreases of approximately
100 and 120 cells/microL with ONGLYZA 5 mg and 10 mg, respectively, relative
to placebo were observed at 24 weeks in a pooled analysis of five placebo-controlled
clinical studies. Similar effects were observed when ONGLYZA 5 mg was given
in initial combination with metformin compared to metformin alone. There was
no difference observed for ONGLYZA 2.5 mg relative to placebo. The proportion
of patients who were reported to have a lymphocyte count â‰¤750 cells/microL
was 0.5%, 1.5%, 1.4%, and 0.4% in the saxagliptin 2.5 mg, 5 mg, 10 mg, and
placebo groups, respectively.  In most patients, recurrence was not observed
with repeated exposure to ONGLYZA although some patients had recurrent decreases
upon rechallenge that led to discontinuation of ONGLYZA. The decreases in
lymphocyte count were not associated with clinically relevant adverse reactions.</p>
<p>The
clinical significance of this decrease in lymphocyte count relative to placebo
is not known. When clinically indicated, such as in settings of unusual or
prolonged <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, lymphocyte count should be measured. The effect of ONGLYZA
on lymphocyte counts in patients with lymphocyte abnormalities (e.g., human
<span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus) is unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.0.1.6.2"></a><a name="section-6.1.7.2"></a><p></p>
<h4>Platelets</h4>
<p class="First">ONGLYZA did not demonstrate a clinically
meaningful or consistent effect on platelet count in the six, double-blind,
controlled clinical safety and efficacy trials.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2  Postmarketing Experience</h2>
<p class="First">Additional adverse reactions have been identified during postapproval use of ONGLYZA. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, and exfoliative skin conditions. [See <span class="Italics"><a href="#s4">Contraindications (4)</a></span> and <span class="Italics"><a href="#s5.3">Warnings and Precautions (5.3)</a></span>.]</li>
<li><span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">Acute pancreatitis</span>. [See <span class="Italics"><a href="#s1.2">Indications and Usage (1.2)</a></span> and <span class="Italics"><a href="#s5.1">Warnings and Precautions (5.1)</a></span>.]</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Strong Inhibitors of CYP3A4/5 Enzymes</h2>
<p class="First">Ketoconazole significantly increased saxagliptin
exposure. Similar significant increases in plasma concentrations of saxagliptin
are anticipated with other strong CYP3A4/5 inhibitors (e.g., atazanavir, clarithromycin,
indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and
telithromycin). The dose of ONGLYZA should be limited to 2.5 mg when coadministered
with a strong CYP3A4/5 inhibitor. [See <span class="Italics"><a href="#s2.3">Dosage and
Administration (2.3)</a></span> and <span class="Italics"><a href="#s12.3">Clinical
Pharmacology (12.3)</a></span>.]</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s8"></a><a name="section-8"></a><p></p>
<h1>8  USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s8.1.1"></a><a name="section-8.1.1"></a><p></p>
<h3>Pregnancy Category B</h3>
<p class="First">There are no adequate and well-controlled
studies in pregnant women. Because animal reproduction studies are not always
predictive of human response, ONGLYZA, like other antidiabetic medications,
should be used during pregnancy only if clearly needed.</p>
<p>Saxagliptin
was not teratogenic at any dose tested when administered to pregnant rats
and rabbits during periods of organogenesis. Incomplete ossification of the
pelvis, a form of <span class="product-label-link" type="condition" conceptid="436077" conceptname="Developmental delay">developmental delay</span>, occurred in rats at a dose of 240 mg/kg,
or approximately 1503 and 66 times human exposure to saxagliptin and the active
metabolite, respectively, at the maximum recommended human dose (MRHD) of
5 mg. Maternal toxicity and reduced fetal body weights were observed at 7986
and 328 times the human exposure at the MRHD for saxagliptin and the active
metabolite, respectively. Minor skeletal variations in rabbits occurred at
a maternally toxic dose of 200 mg/kg, or approximately 1432 and 992 times
the MRHD.</p>
<p>Coadministration of saxagliptin and metformin, to pregnant rats and rabbits during the period of organogenesis, was neither embryolethal nor teratogenic in either species when tested at doses yielding systemic exposures (AUC) up to 100 and 10 times the MRHD (saxagliptin 5 mg and metformin 2000 mg), respectively, in rats; and 249 and 1.1 times the MRHDs in rabbits. In rats, minor developmental toxicity was limited to an increased incidence of wavy ribs; associated maternal toxicity was limited to weight decrements of 11% to 17% over the course of the study, and related reductions in maternal food consumption. In rabbits, coadministration was poorly tolerated in a subset of mothers (12 of 30), resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, moribundity, or abortion. However, among surviving mothers with evaluable litters, maternal toxicity was limited to marginal reductions in body weight over the course of gestation days 21 to 29; and associated developmental toxicity in these litters was limited to fetal body weight decrements of 7%, and a low incidence of delayed ossification of the fetal hyoid.</p>
<p>Saxagliptin
administered to female rats from gestation day 6 to lactation day 20 resulted
in decreased body weights in male and female offspring only at maternally
toxic doses (exposures â‰¥1629 and 53 times saxagliptin and its active metabolite
at the MRHD). No functional or behavioral toxicity was observed in offspring
of rats administered saxagliptin at any dose.</p>
<p>Saxagliptin
crosses the placenta into the fetus following dosing in pregnant rats.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Saxagliptin is secreted in the milk
of lactating rats at approximately a 1:1 ratio with plasma drug concentrations.
It is not known whether saxagliptin is secreted in human milk. Because many
drugs are secreted in human milk, caution should be exercised when ONGLYZA
is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of ONGLYZA
in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">In the six, double-blind, controlled
clinical safety and efficacy trials of ONGLYZA, 634 (15.3%) of the 4148 randomized
patients were 65 years and over, and 59 (1.4%) patients were 75 years and
over. No overall differences in safety or effectiveness were observed between
patients â‰¥65 years old and the younger patients. While this clinical experience
has not identified differences in responses between the elderly and younger
patients, greater sensitivity of some older individuals cannot be ruled out.</p>
<p>Saxagliptin
and its active metabolite are eliminated in part by the kidney. Because elderly
patients are more likely to have decreased renal function, care should be
taken in dose selection in the elderly based on renal function. [See <span class="Italics"><a href="#s2.2">Dosage and Administration (2.2)</a></span> and <span class="Italics"><a href="#s12.3">Clinical Pharmacology (12.3)</a></span>.]</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">In a controlled clinical trial, once-daily,
orally-administered ONGLYZA in healthy subjects at doses up to 400 mg daily
for 2 weeks (80 times the MRHD) had no dose-related clinical adverse reactions
and no clinically meaningful effect on QTc interval or heart rate.</p>
<p>In
the event of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, appropriate supportive treatment should be initiated
as dictated by the patientâ€™s clinical status. Saxagliptin and its active metabolite
are removed by hemodialysis (23% of dose over 4 hours).</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Saxagliptin is an orally-active inhibitor
of the DPP4 enzyme.</p>
<p>Saxagliptin monohydrate is described
chemically as (1<span class="Italics">S</span>,3<span class="Italics">S</span>,5<span class="Italics">S</span>)-2-[(2<span class="Italics">S</span>)-2-Amino-2-(3-hydroxytricyclo[3.3.1.1<span class="Sup">3,7</span>]dec-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile,
monohydrate or (1<span class="Italics">S</span>,3<span class="Italics">S</span>,5<span class="Italics">S</span>)-2-[(2<span class="Italics">S</span>)-2-Amino-2-(3-hydroxyadamantan-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile hydrate. The empirical formula is C<span class="Sub">18</span>H<span class="Sub">25</span>N<span class="Sub">3</span>O<span class="Sub">2</span>â€¢H<span class="Sub">2</span>O and the molecular weight
is 333.43. The structural formula is:</p>
<div class="Figure"><img alt="Saxagliptin Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d45fc842-2563-4421-86af-a55b3191e19b&amp;name=saxagliptin-struct.jpg"></div>
<p>Saxagliptin monohydrate
is a white to light yellow or light brown, non-hygroscopic, crystalline powder.
It is sparingly soluble in water at 24Â°C Â± 3Â°C, slightly soluble in ethyl
acetate, and soluble in methanol, ethanol, isopropyl alcohol, acetonitrile,
acetone, and polyethylene glycol 400 (PEG 400).</p>
<p>Each
film-coated tablet of ONGLYZA for oral use contains either 2.79 mg saxagliptin
hydrochloride (anhydrous) equivalent to 2.5 mg saxagliptin or 5.58 mg saxagliptin
hydrochloride (anhydrous) equivalent to 5 mg saxagliptin and the following
inactive ingredients: lactose monohydrate, microcrystalline cellulose, croscarmellose
sodium, and magnesium stearate. In addition, the film coating contains the
following inactive ingredients: polyvinyl alcohol, polyethylene glycol, titanium
dioxide, talc, and iron oxides.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Increased concentrations of the incretin
hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic
polypeptide (GIP) are released into the bloodstream from the small intestine
in response to meals. These hormones cause insulin release from the pancreatic
beta cells in a glucose-dependent manner but are inactivated by the DPP4 enzyme within minutes. GLP-1 also lowers glucagon secretion
from pancreatic alpha cells, reducing hepatic glucose production. In patients
with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, concentrations of GLP-1 are reduced but the insulin
response to GLP-1 is preserved. Saxagliptin is a competitive DPP4 inhibitor
that slows the inactivation of the incretin hormones, thereby increasing their
bloodstream concentrations and reducing fasting and postprandial glucose concentrations
in a glucose-dependent manner in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="s12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">In patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus,
administration of ONGLYZA inhibits DPP4 enzyme activity for a 24-hour period.
After an oral glucose load or a meal, this DPP4 inhibition resulted in a 2-
to 3-fold increase in circulating levels of active GLP-1 and GIP, decreased
glucagon concentrations, and increased glucose-dependent insulin secretion
from pancreatic beta cells. The rise in insulin and decrease in glucagon were
associated with lower fasting glucose concentrations and reduced glucose excursion
following an oral glucose load or a meal.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s12.2.2"></a><a name="section-11.2.1"></a><p></p>
<h3>Cardiac Electrophysiology</h3>
<p class="First">In a randomized, double-blind, placebo-controlled,
4-way crossover, active comparator study using moxifloxacin in 40 healthy
subjects, ONGLYZA was not associated with clinically meaningful prolongation
of the QTc interval or heart rate at daily doses up to 40 mg (8 times the
MRHD).</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The pharmacokinetics of saxagliptin
and its active metabolite, 5-hydroxy saxagliptin were similar in healthy subjects
and in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. The C<span class="Sub">max </span>and
AUC values of saxagliptin and its active metabolite increased proportionally
in the 2.5 to 400 mg dose range. Following a 5 mg single oral dose of saxagliptin
to healthy subjects, the mean plasma AUC values for saxagliptin and its active
metabolite were 78 ngâ€¢h/mL and 214 ngâ€¢h/mL, respectively. The corresponding
plasma C<span class="Sub">max</span> values were 24 ng/mL and 47 ng/mL, respectively.
The average variability (%CV) for AUC and C<span class="Sub">max </span> for
both saxagliptin and its active metabolite was less than 25%.</p>
<p>No
appreciable accumulation of either saxagliptin or its active metabolite was
observed with repeated once-daily dosing at any dose level. No dose- and time-<span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>
were observed in the clearance of saxagliptin and its active metabolite over
14 days of once-daily dosing with saxagliptin at doses ranging from 2.5 to
400 mg.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s12.3.1"></a><a name="section-11.3.1"></a><p></p>
<h3>Absorption</h3>
<p class="First">The median time to maximum concentration
(T<span class="Sub">max</span>) following the 5 mg once daily dose was 2 hours
for saxagliptin and 4 hours for its active metabolite. Administration with
a high-fat meal resulted in an increase in T<span class="Sub">max</span> of
saxagliptin by approximately 20 minutes as compared to fasted conditions.
There was a 27% increase in the AUC of saxagliptin when given with a meal
as compared to fasted conditions. ONGLYZA may be administered with or without
food.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12.3.2"></a><a name="section-11.3.2"></a><p></p>
<h3>Distribution</h3>
<p class="First">The <span class="Italics">in vitro</span> protein
binding of saxagliptin and its active metabolite in human serum is negligible.
Therefore, changes in blood protein levels in various disease states (e.g.,
renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>) are not expected to alter the disposition of
saxagliptin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12.3.3"></a><a name="section-11.3.3"></a><p></p>
<h3>Metabolism</h3>
<p class="First">The metabolism of saxagliptin is
primarily mediated by cytochrome P450 3A4/5 (CYP3A4/5). The major metabolite
of saxagliptin is also a DPP4 inhibitor, which is one-half as potent as saxagliptin.
Therefore, strong CYP3A4/5 inhibitors and inducers will alter the pharmacokinetics
of saxagliptin and its active metabolite. [See <span class="Italics"><a href="#s7">Drug
Interactions (7)</a></span>.]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12.3.4"></a><a name="section-11.3.4"></a><p></p>
<h3>Excretion</h3>
<p class="First">Saxagliptin is eliminated by both
renal and hepatic pathways. Following a single 50 mg dose of <span class="Sup">14</span>C-saxagliptin,
24%, 36%, and 75% of the dose was excreted in the urine as saxagliptin, its
active metabolite, and total radioactivity, respectively. The average renal
clearance of saxagliptin (~230 mL/min) was greater than the average estimated
glomerular filtration rate (~120 mL/min), suggesting some active renal excretion.
A total of 22% of the administered radioactivity was recovered in feces representing
the fraction of the saxagliptin dose excreted in bile and/or unabsorbed drug
from the gastrointestinal tract. Following a single oral dose of ONGLYZA 5
mg to healthy subjects, the mean plasma terminal half-life (t<span class="Sub">1/2</span>)
for saxagliptin and its active metabolite was 2.5 and 3.1 hours, respectively.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s12.3.5"></a><a name="section-11.3.5"></a><p></p>
<h3>Specific Populations</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="s12.3.5.1"></a><a name="section-11.3.5.1"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h4>
<p class="First">A single-dose, open-label study was
conducted to evaluate the pharmacokinetics of saxagliptin (10 mg dose) in
subjects with varying degrees of <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic renal impairment</span> (N=8 per group)
compared to subjects with normal renal function. The study included patients
with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> classified on the basis of creatinine clearance as mild
(&gt;50 to â‰¤80 mL/min), moderate (30 to â‰¤50 mL/min), and severe (&lt;30 mL/min),
as well as patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> on hemodialysis. Creatinine
clearance was estimated from serum creatinine based on the Cockcroft-Gault
formula:</p>
<a name="i1232184d-5dde-4723-8f66-51d2de9c9a89"></a><table border="0" cellpadding="2" cellspacing="1" width="80%">
<colgroup>
<col width="30%">
<col width="37%">
<col width="33%">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td align="right">CrCl = </td>
<td class="Botrule">[140 âˆ’ age (years)] Ã— weight (kg) </td>
<td>{Ã— 0.85 for female patients}</td>
</tr>
<tr class="Last">
<td>Â </td>
<td align="left">[72 Ã— serum creatinine (mg/dL)]</td>
<td>Â </td>
</tr>
</tbody>
</table>
<p>The degree of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> did not affect the C<span class="Sub">max</span> of
saxagliptin or its active metabolite. In subjects with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>,
the AUC values of saxagliptin and its active metabolite were  20% and 70%
higher, respectively, than AUC values in subjects with normal renal function.
Because increases of this magnitude are not considered to be clinically relevant,
dosage adjustment in patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is not recommended.
In subjects with moderate or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the AUC values of saxagliptin
and its active metabolite were up to 2.1- and 4.5-fold higher, respectively,
than AUC values in subjects with normal renal function. To achieve plasma
exposures of saxagliptin and its active metabolite similar to those in patients
with normal renal function, the recommended dose is 2.5 mg once daily in patients
with moderate and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, as well as in patients with end-stage
<span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> requiring hemodialysis. Saxagliptin is removed by hemodialysis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12.3.5.2"></a><a name="section-11.3.5.2"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h4>
<p class="First">In subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>
(Child-Pugh classes A, B, and C), mean C<span class="Sub">max</span> and AUC
of saxagliptin were up to 8% and 77% higher, respectively, compared to healthy
matched controls following administration of a single 10 mg dose of saxagliptin.
The corresponding C<span class="Sub">max </span>and AUC of the active metabolite
were up to 59% and 33% lower, respectively, compared to healthy matched controls.
These differences are not considered to be clinically meaningful. No dosage
adjustment is recommended for patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12.3.5.4"></a><a name="section-11.3.5.3"></a><p></p>
<h4>Body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Mass</span> Index</h4>
<p class="First">No dosage adjustment is recommended
based on body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index (BMI) which was not identified as a significant covariate
on the apparent clearance of saxagliptin or its active metabolite in the population
pharmacokinetic analysis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12.3.5.5"></a><a name="section-11.3.5.4"></a><p></p>
<h4>Gender</h4>
<p class="First">No
dosage adjustment is recommended based on gender. There were no differences
observed in saxagliptin pharmacokinetics between males and females. Compared
to males, females had approximately 25% higher exposure values for the active
metabolite than males, but this difference is unlikely to be of clinical relevance.
Gender was not identified as a significant covariate on the apparent clearance
of saxagliptin and its active metabolite in the population pharmacokinetic
analysis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12.3.5.6"></a><a name="section-11.3.5.5"></a><p></p>
<h4>Geriatric</h4>
<p class="First">No dosage adjustment is recommended
based on age alone. Elderly subjects (65-80 years) had 23% and 59% higher
geometric mean C<span class="Sub">max</span> and geometric mean AUC values,
respectively, for saxagliptin than young subjects (18-40 years). Differences
in active metabolite pharmacokinetics between elderly and young subjects generally
reflected the differences observed in saxagliptin pharmacokinetics. The difference
between the pharmacokinetics of saxagliptin and the active metabolite in young
and elderly subjects is likely due to multiple factors including declining
renal function and metabolic capacity with increasing age. Age was not identified
as a significant covariate on the apparent clearance of saxagliptin and its
active metabolite in the population pharmacokinetic analysis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12.3.5.7"></a><a name="section-11.3.5.6"></a><p></p>
<h4>Pediatric</h4>
<p class="First">Studies characterizing the pharmacokinetics
of saxagliptin in pediatric patients have not been performed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12.3.12"></a><a name="section-11.3.5.7"></a><p></p>
<h4>Race and Ethnicity</h4>
<p class="First">No dosage adjustment is recommended
based on race. The population pharmacokinetic analysis compared the pharmacokinetics
of saxagliptin and its active metabolite in 309 Caucasian subjects with 105
non-Caucasian subjects (consisting of six racial groups). No significant difference
in the pharmacokinetics of saxagliptin and its active metabolite were detected
between these two populations.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12.3.6"></a><a name="section-11.3.6"></a><p></p>
<h3>Drug-Drug Interactions</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="s12.3.6.1"></a><a name="section-11.3.6.1"></a><p></p>
<h4>In Vitro Assessment of Drug Interactions</h4>
<p class="First">The metabolism of saxagliptin is primarily
mediated by CYP3A4/5.</p>
<p>In<span class="Italics"> in vitro</span> studies,
saxagliptin and its active metabolite did not inhibit CYP1A2, 2A6, 2B6, 2C9,
2C19, 2D6, 2E1, or 3A4, or induce CYP1A2, 2B6, 2C9, or 3A4. Therefore, saxagliptin
is not expected to alter the metabolic clearance of coadministered drugs that
are metabolized by these enzymes. Saxagliptin is a P-glycoprotein (P-gp) substrate
but is not a significant inhibitor or inducer of P-gp.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12.3.6.2"></a><a name="section-11.3.6.2"></a><p></p>
<h4>In Vivo Assessment of Drug Interactions</h4>
<a name="ie98eda56-8fe3-4953-86e5-f581699ccc28"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 3: Effect of Coadministered Drugs on Systemic Exposures of Saxagliptin and its Active Metabolite, 5-hydroxy Saxagliptin</span></caption>
<colgroup>
<col width="20%">
<col width="22%">
<col width="18%">
<col width="20%">
<col width="10%">
<col width="10%">
</colgroup>
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule" align="left" valign="top">Coadministered Drug</th>
<th class="Lrule Rrule Toprule" valign="top">Dose of<br>Coadministered Drug*</th>
<th class="Lrule Rrule Toprule" valign="top">Dosing of<br>Saxagliptin*</th>
<th class="Lrule Rrule Toprule" align="center" colspan="3" valign="top"><span class="Bold">Geometric Mean Ratio<br>(ratio with/without coadministered drug)<br>No Effect = 1.00</span></th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule">Â </th>
<th class="Botrule Lrule Rrule">Â </th>
<th class="Botrule Lrule Rrule">Â </th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Â </span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">AUC<span class="Sup">â€ </span></span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">C<span class="Sub">max</span></span></th>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="6">* Single dose unless otherwise noted</td></tr>
<tr><td colspan="6">
<span class="Sup">â€ </span> AUC = AUC(INF) for drugs given as single dose and AUC = AUC(TAU) for drugs given in multiple doses</td></tr>
<tr><td colspan="6">
<span class="Sup">â€¡</span> Results exclude one subject</td></tr>
<tr><td colspan="6">
<span class="Sup">Â§</span> The plasma dipeptidyl peptidase-4 (DPP4) activity inhibition over a 24-hour dose interval was not affected by rifampin.</td></tr>
<tr class="Last"><td colspan="6">ND=not determined; QD=once daily; q6h=every 6 hours; q12h=every 12 hours; BID=twice daily; LA=long acting</td></tr>
</tfoot>
<tbody>
<tr class="First"><th class="Botrule Lrule Rrule" align="left" colspan="6"><span class="Bold">No dosing adjustments required for the following:</span></th></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Metformin</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1000 mg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">100 mg</td>
<td class="Botrule Lrule Rrule Toprule">saxagliptin<br>5-hydroxy saxagliptin</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.98<br>0.99</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.79<br>0.88</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Glyburide</td>
<td class="Botrule Lrule Rrule Toprule" align="center">5 mg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10 mg</td>
<td class="Botrule Lrule Rrule Toprule">saxagliptin<br>5-hydroxy saxagliptin</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.98<br>ND</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.08<br>ND</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Pioglitazone<span class="Sup">â€¡</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">45 mg QD for 10 days</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10 mg QD for 5 days</td>
<td class="Botrule Lrule Rrule Toprule">saxagliptin<br>5-hydroxy saxagliptin</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.11<br>ND</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.11<br>ND</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Digoxin</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.25 mg q6h first day followed by q12h second day followed by QD for<br>5 days</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10 mg QD for 7 days</td>
<td class="Botrule Lrule Rrule Toprule">saxagliptin<br>5-hydroxy saxagliptin</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.05<br>1.06</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.99<br>1.02</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Simvastatin</td>
<td class="Botrule Lrule Rrule Toprule" align="center">40 mg QD for 8 days</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10 mg QD for 4 days</td>
<td class="Botrule Lrule Rrule Toprule">saxagliptin<br>5-hydroxy saxagliptin</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.12<br>1.02</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.21<br>1.08</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Diltiazem</td>
<td class="Botrule Lrule Rrule Toprule" align="center">360 mg LA QD for 9 days</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10 mg</td>
<td class="Botrule Lrule Rrule Toprule">saxagliptin<br>5-hydroxy saxagliptin</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2.09<br>0.66</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.63<br>0.57</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Rifampin<span class="Sup">Â§</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">600 mg QD for 6 days</td>
<td class="Botrule Lrule Rrule Toprule" align="center">5 mg</td>
<td class="Botrule Lrule Rrule Toprule">saxagliptin<br>5-hydroxy saxagliptin</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.24<br>1.03</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.47<br>1.39</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Omeprazole</td>
<td class="Botrule Lrule Rrule Toprule" align="center">40 mg QD for 5 days</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10 mg</td>
<td class="Botrule Lrule Rrule Toprule">saxagliptin<br>5-hydroxy saxagliptin</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.13<br>ND</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.98<br>ND</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Aluminum hydroxide + magnesium hydroxide + simethicone</td>
<td class="Botrule Lrule Rrule Toprule" align="center">aluminum hydroxide:<br>2400 mg<br>magnesium hydroxide:<br>2400 mg<br>simethicone: 240 mg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10 mg</td>
<td class="Botrule Lrule Rrule Toprule">saxagliptin<br>5-hydroxy saxagliptin</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.97<br>ND</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.74<br>ND</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Famotidine</td>
<td class="Botrule Lrule Rrule Toprule" align="center">40 mg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10 mg</td>
<td class="Botrule Lrule Rrule Toprule">saxagliptin<br>5-hydroxy saxagliptin</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.03<br>ND</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.14<br>ND</td>
</tr>
<tr><th class="Botrule Lrule Rrule Toprule" align="left" colspan="6"><span class="Bold">Limit ONGLYZA dose to 2.5 mg once daily when coadministered with strong CYP3A4/5 inhibitors:</span></th></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Ketoconazole</td>
<td class="Botrule Lrule Rrule Toprule" align="center">200 mg BID for 9 days</td>
<td class="Botrule Lrule Rrule Toprule" align="center">100 mg</td>
<td class="Botrule Lrule Rrule Toprule">saxagliptin<br>5-hydroxy saxagliptin</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2.45<br>0.12</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.62<br>0.05</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule">Ketoconazole</td>
<td class="Botrule Lrule Rrule Toprule" align="center">200 mg BID for 7 days</td>
<td class="Botrule Lrule Rrule Toprule" align="center">20 mg</td>
<td class="Botrule Lrule Rrule Toprule">saxagliptin<br>5-hydroxy saxagliptin</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3.67<br>ND</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2.44<br>ND</td>
</tr>
</tbody>
</table>
<a name="i26e51378-1ccb-4769-8808-48c262fb7f4d"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 4: Effect of Saxagliptin on Systemic Exposures of Coadministered Drugs</span></caption>
<colgroup>
<col width="20%">
<col width="22%">
<col width="20%">
<col width="18%">
<col width="10%">
<col width="10%">
</colgroup>
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule" align="left" valign="top">Coadministered Drug</th>
<th class="Lrule Rrule Toprule" valign="top">Dose of<br>Coadministered Drug*</th>
<th class="Lrule Rrule Toprule" valign="top">Dosing of<br>Saxagliptin*</th>
<th class="Lrule Rrule Toprule" align="center" colspan="3" valign="top"><span class="Bold">Geometric Mean Ratio<br>(ratio with/without saxagliptin)<br>No Effect = 1.00</span></th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule">Â </th>
<th class="Botrule Lrule Rrule">Â </th>
<th class="Botrule Lrule Rrule">Â </th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Â </span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">AUC<span class="Sup">â€ </span></span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">C<span class="Sub">max</span></span></th>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Toprule" colspan="6">* Single dose unless otherwise noted</td></tr>
<tr><td colspan="6">
<span class="Sup">â€ </span> AUC = AUC(INF) for drugs given as single dose and AUC = AUC(TAU) for drugs given in multiple doses</td></tr>
<tr><td colspan="6">
<span class="Sup">â€¡</span> Results include all subjects</td></tr>
<tr class="Last"><td colspan="6">ND=not determined; QD=once daily; q6h=every 6 hours; q12h=every 12 hours; BID=twice daily; LA=long acting</td></tr>
</tfoot>
<tbody>
<tr class="First"><th class="Botrule Lrule Rrule" align="left" colspan="6"><span class="Bold">No dosing adjustments required for the following:</span></th></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Metformin</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1000 mg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">100 mg</td>
<td class="Botrule Lrule Rrule Toprule">metformin</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.20</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.09</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Glyburide</td>
<td class="Botrule Lrule Rrule Toprule" align="center">5 mg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10 mg</td>
<td class="Botrule Lrule Rrule Toprule">glyburide</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.06</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.16</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Pioglitazone<span class="Sup">â€¡</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">45 mg QD for 10 days</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10 mg QD for 5 days</td>
<td class="Botrule Lrule Rrule Toprule">pioglitazone<br>hydroxy-pioglitazone</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.08<br>ND</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.14<br>ND</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Digoxin</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.25 mg q6h first day followed by q12h second day followed by QD for<br>5 days</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10 mg QD for 7 days</td>
<td class="Botrule Lrule Rrule Toprule">digoxin</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.06</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.09</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Simvastatin</td>
<td class="Botrule Lrule Rrule Toprule" align="center">40 mg QD for 8 days</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10 mg QD for 4 days</td>
<td class="Botrule Lrule Rrule Toprule">simvastatin<br>simvastatin acid</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.04<br>1.16</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.88<br>1.00</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Diltiazem</td>
<td class="Botrule Lrule Rrule Toprule" align="center">360 mg LA QD for 9 days</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10 mg</td>
<td class="Botrule Lrule Rrule Toprule">diltiazem</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.10</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.16</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Ketoconazole</td>
<td class="Botrule Lrule Rrule Toprule" align="center">200 mg BID for 9 days</td>
<td class="Botrule Lrule Rrule Toprule" align="center">100 mg</td>
<td class="Botrule Lrule Rrule Toprule">ketoconazole</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.87</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.84</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule">Ethinyl estradiol and Norgestimate</td>
<td class="Botrule Lrule Rrule Toprule" align="center">ethinyl estradiol 0.035 mg and norgestimate 0.250 mg 
for 21 days</td>
<td class="Botrule Lrule Rrule Toprule" align="center">5 mg QD for 21 days</td>
<td class="Botrule Lrule Rrule Toprule">ethinyl estradiol<br>norelgestromin<br>norgestrel</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.07<br>1.10<br>1.13<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.98<br>1.09<br>1.17<br>
</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"> Saxagliptin did not induce tumors
in either mice (50, 250, and 600 mg/kg) or rats (25, 75, 150, and 300 mg/kg)
at the highest doses evaluated. The highest doses evaluated in mice were equivalent
to approximately 870 (males) and 1165 (females) times the human exposure at
the MRHD of 5 mg/day. In rats, exposures were approximately 355 (males) and
2217 (females) times the MRHD.</p>
<p>Saxagliptin was not mutagenic
or clastogenic with or without metabolic activation in an <span class="Italics">in vitro</span> Ames
bacterial assay, an <span class="Italics">in vitro</span> cytogenetics assay in primary
human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, an <span class="Italics">in vivo</span> oral micronucleus assay in
rats, an <span class="Italics">in vivo</span> oral DNA repair study in rats, and an oral <span class="Italics">in
vivo</span>/<span class="Italics">in vitro</span> cytogenetics study in rat peripheral
blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. The active metabolite was not mutagenic in an <span class="Italics">in
vitro</span> Ames bacterial assay.</p>
<p>In a rat fertility
study, males were treated with oral gavage doses for 2 weeks prior to mating,
during mating, and up to scheduled termination (approximately 4 weeks total)
and females were treated with oral gavage doses for 2 weeks prior to mating
through gestation day 7. No adverse effects on fertility were observed at
exposures of approximately 603 (males) and 776 (females) times the MRHD. Higher
doses that elicited maternal toxicity also increased fetal resorptions (approximately
2069 and 6138 times the MRHD). Additional effects on estrous cycling, fertility,
ovulation, and implantation were observed at approximately 6138 times the
MRHD.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="s13.2.1"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology</h2>
<p class="First">Saxagliptin produced adverse skin
changes in the extremities of cynomolgus monkeys (<span class="product-label-link" type="condition" conceptid="4320339" conceptname="Crust">scabs</span> and/or ulceration
of tail, digits, scrotum, and/or nose). <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">Skin lesions</span> were reversible at â‰¥20
times the MRHD but in some cases were irreversible and necrotizing at higher
exposures. Adverse skin changes were not observed at exposures similar to
(1 to 3 times) the MRHD of 5 mg. Clinical correlates to <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">skin lesions</span> in monkeys
have not been observed in human clinical trials of saxagliptin.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">ONGLYZA has been studied as monotherapy
and in combination with metformin, glyburide, and thiazolidinedione (pioglitazone
and rosiglitazone) therapy.</p>
<p>A total of 4148 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>
mellitus were randomized in six, double-blind, controlled clinical trials
conducted to evaluate the safety and glycemic efficacy of ONGLYZA. A total
of 3021 patients in these trials were treated with ONGLYZA. In these trials,
the mean age was 54 years, and 71% of patients were Caucasian, 16% were Asian,
4% were black, and 9% were of other racial groups. An additional 423 patients,
including 315 who received ONGLYZA, participated in a placebo-controlled,
dose-ranging study of 6 to 12 weeks in duration.</p>
<p>In
these six, double-blind trials, ONGLYZA was evaluated at doses of 2.5 mg and
5 mg once daily. Three of these trials also evaluated a saxagliptin dose of
10 mg daily. The 10 mg daily dose of saxagliptin did not provide greater efficacy
than the 5 mg daily dose. Treatment with ONGLYZA at all doses produced clinically
relevant and statistically significant improvements in hemoglobin A1c (A1C),
fasting plasma glucose (FPG), and 2-hour  postprandial glucose (PPG) following
a standard oral glucose tolerance test (OGTT), compared to control. Reductions
in A1C were seen across subgroups including gender, age, race, and baseline
BMI.</p>
<p>ONGLYZA was not associated with significant changes
from baseline in body weight or fasting serum lipids compared to placebo.</p>
<p>ONGLYZA has also been evaluated in three additional trials in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>: an active-controlled trial comparing add-on therapy with ONGLYZA to glipizide in 858 patients inadequately controlled on metformin alone, a trial comparing ONGLYZA to placebo in 455 patients inadequately controlled on insulin alone or on insulin in combination with metformin, and a trial comparing ONGLYZA to placebo in 170 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and moderate or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or ESRD.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Monotherapy</h2>
<p class="First">A total of 766 patients with type
2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> inadequately controlled on diet and exercise (A1C â‰¥7% to â‰¤10%)
participated in two 24-week, double-blind, placebo-controlled trials evaluating
the efficacy and safety of ONGLYZA monotherapy.</p>
<p>In the
first trial, following a 2-week single-blind diet, exercise, and placebo lead-in
period, 401 patients were randomized to 2.5 mg, 5 mg, or 10 mg of ONGLYZA
or placebo. Patients who failed to meet specific glycemic goals during the
study were treated with metformin rescue therapy, added on to placebo or ONGLYZA.
Efficacy was evaluated at the last measurement prior to rescue therapy for
patients needing rescue. Dose titration of ONGLYZA was not permitted. </p>
<p>Treatment
with ONGLYZA 2.5 mg and 5 mg daily provided significant improvements in A1C,
FPG, and PPG compared to placebo (Table 5). The percentage of patients who
discontinued for lack of glycemic control or who were rescued for meeting
prespecified glycemic criteria was 16% in the ONGLYZA 2.5 mg treatment group,
20% in the ONGLYZA 5 mg treatment group, and 26% in the placebo group.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s14.1.2"></a><a name="section-13.1.1"></a><p></p>
<a name="i869e9daa-6c26-4012-8e1a-fb7e51ce4ca5"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 5: Glycemic Parameters at Week 24 in a Placebo-Controlled Study
of ONGLYZA Monotherapy in Patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span>*</span></caption>
<colgroup>
<col width="40%">
<col width="20%">
<col width="20%">
<col width="20%">
</colgroup>
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Efficacy
Parameter</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">ONGLYZA<br>2.5
mg<br>N=102</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">ONGLYZA<br>5
mg<br>N=106</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Placebo<br><br>N=95</span></th>
</tr></thead>
<tfoot>
<tr class="First"><td colspan="4">*Â Â Intent-to-treat population
using last observation on study or last observation prior to metformin rescue
therapy for patients needing rescue.</td></tr>
<tr><td colspan="4">
<span class="Sup">â€ </span>Â Â Least
squares mean adjusted for baseline value.</td></tr>
<tr><td colspan="4">
<span class="Sup">â€¡</span>Â Â p-value
&lt;0.0001 compared to placebo</td></tr>
<tr><td colspan="4">
<span class="Sup">Â§</span>Â Â p-value
&lt;0.05 compared to placebo</td></tr>
<tr class="Last"><td colspan="4">
<span class="Sup">Â¶</span>Â Â Significance
was not tested for the 2-hour PPG for the 2.5 mg dose of ONGLYZA.</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule"><span class="Bold">Hemoglobin A1C (%)</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=100</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=103</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=92</span></td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Baseline (mean)</td>
<td class="Lrule Rrule" align="center">7.9</td>
<td class="Lrule Rrule" align="center">8.0</td>
<td class="Lrule Rrule" align="center">7.9</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Change from
baseline (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’0.4</td>
<td class="Lrule Rrule" align="center">âˆ’0.5</td>
<td class="Lrule Rrule" align="center">+0.2</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Difference
from placebo (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’0.6<span class="Sup">â€¡</span>
</td>
<td class="Lrule Rrule" align="center">âˆ’0.6<span class="Sup">â€¡</span>
</td>
<td class="Lrule Rrule" align="center">Â </td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Â Â 95%
Confidence Interval</td>
<td class="Lrule Rrule" align="center">(âˆ’0.9, âˆ’0.3)</td>
<td class="Lrule Rrule" align="center">(âˆ’0.9, âˆ’0.4)</td>
<td class="Lrule Rrule" align="center">Â </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Percent
of patients achieving A1C &lt;7%</td>
<td class="Botrule Lrule Rrule" align="center">35% (35/100)</td>
<td class="Botrule Lrule Rrule" align="center">38%<span class="Sup">Â§</span> (39/103)</td>
<td class="Botrule Lrule Rrule" align="center">24% (22/92)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"><span class="Bold">Fasting Plasma Glucose (mg/dL)</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=101</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=105</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=92</span></td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Baseline (mean)</td>
<td class="Lrule Rrule" align="center">178</td>
<td class="Lrule Rrule" align="center">171</td>
<td class="Lrule Rrule" align="center">172</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Change from
baseline (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’15</td>
<td class="Lrule Rrule" align="center">âˆ’9</td>
<td class="Lrule Rrule" align="center">+6</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Difference
from placebo (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’21<span class="Sup">Â§</span>
</td>
<td class="Lrule Rrule" align="center">âˆ’15<span class="Sup">Â§</span>
</td>
<td class="Lrule Rrule" align="center">Â </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â 95%
Confidence Interval</td>
<td class="Botrule Lrule Rrule" align="center">(âˆ’31, âˆ’10)</td>
<td class="Botrule Lrule Rrule" align="center">(âˆ’25, âˆ’4)</td>
<td class="Botrule Lrule Rrule" align="center">Â </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"><span class="Bold">2-hour Postprandial Glucose (mg/dL)</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=78</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=84</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=71</span></td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Baseline (mean)</td>
<td class="Lrule Rrule" align="center">279</td>
<td class="Lrule Rrule" align="center">278</td>
<td class="Lrule Rrule" align="center">283</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Change from
baseline (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’45</td>
<td class="Lrule Rrule" align="center">âˆ’43</td>
<td class="Lrule Rrule" align="center">âˆ’6</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Difference
from placebo (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’39<span class="Sup">Â¶</span>
</td>
<td class="Lrule Rrule" align="center">âˆ’37<span class="Sup">Â§</span>
</td>
<td class="Lrule Rrule" align="center">Â </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule">Â Â Â Â 95%
Confidence Interval</td>
<td class="Botrule Lrule Rrule" align="center">(âˆ’61, âˆ’16)</td>
<td class="Botrule Lrule Rrule" align="center">(âˆ’59, âˆ’15)</td>
<td class="Botrule Lrule Rrule" align="center">Â </td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14.1.3"></a><a name="section-13.1.2"></a><p></p>
<p class="First">A second 24-week monotherapy trial
was conducted to assess a range of dosing regimens for ONGLYZA. Treatment-naive
patients with inadequately controlled <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (A1C â‰¥7% to â‰¤10%) underwent
a 2-week, single-blind diet, exercise, and placebo lead-in period. A total
of 365 patients were randomized to 2.5 mg every morning, 5 mg every morning,
2.5 mg with possible titration to 5 mg every morning, or 5 mg every evening
of ONGLYZA, or placebo. Patients who failed to meet specific glycemic goals
during the study were treated with metformin rescue therapy added on to placebo
or ONGLYZA; the number of patients randomized per treatment group ranged from
71 to 74.</p>
<p>Treatment with either ONGLYZA 5 mg every morning
or 5 mg every evening provided significant improvements in A1C versus placebo
(mean placebo-corrected reductions of âˆ’0.4% and âˆ’0.3%, respectively). Treatment
with ONGLYZA 2.5 mg every morning also provided significant improvement in
A1C versus placebo (mean placebo-corrected reduction of âˆ’0.4%).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Combination Therapy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s14.2.1"></a><a name="section-13.2.1"></a><p></p>
<h3>Add-On Combination Therapy with Metformin</h3>
<p class="First">A total of 743 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>
participated in this 24-week, randomized, double-blind, placebo-controlled
trial to evaluate the efficacy and safety of ONGLYZA in combination with metformin
in patients with inadequate glycemic control (A1C  â‰¥7% and â‰¤10%) on metformin
alone. To qualify for enrollment, patients were required to be on a stable
dose of metformin (1500-2550 mg daily) for at least 8 weeks.</p>
<p>Patients
who met eligibility criteria were enrolled in a single-blind, 2-week, dietary
and exercise placebo lead-in period during which patients received metformin
at their pre-study dose, up to 2500 mg daily.
Following the lead-in period, eligible patients were randomized to 2.5 mg,
5 mg, or 10 mg of ONGLYZA or placebo in addition to their current dose of
open-label metformin. Patients who failed to meet specific glycemic goals
during the study were treated with pioglitazone rescue therapy, added on to
existing study medications. Dose titrations of ONGLYZA and metformin were
not permitted.</p>
<p>ONGLYZA 2.5 mg and 5 mg add-on to metformin
provided significant improvements in A1C, FPG, and PPG compared with placebo
add-on to metformin (Table 6). Mean changes from baseline for A1C over time
and at endpoint are shown in Figure 1. The proportion of patients who discontinued
for lack of glycemic control or who were rescued for meeting prespecified
glycemic criteria was 15% in the ONGLYZA 2.5 mg add-on to metformin group,
13% in the ONGLYZA 5 mg add-on to metformin group, and 27% in the placebo
add-on to metformin group.</p>
<a name="ib942d808-c446-4785-8dd4-edfe64bd4f0f"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 6: Glycemic Parameters at Week 24 in a Placebo-Controlled Study
of ONGLYZA as Add-On Combination Therapy with Metformin*</span></caption>
<colgroup>
<col width="40%">
<col width="20%">
<col width="20%">
<col width="20%">
</colgroup>
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Efficacy
Parameter</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">ONGLYZA
2.5 mg<br>+<br>Metformin<br>N=192</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">ONGLYZA
5 mg<br>+<br>Metformin<br>N=191</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Placebo<br>+<br>Metformin<br>N=179</span></th>
</tr></thead>
<tfoot>
<tr class="First"><td colspan="4">*Â Â Intent-to-treat population
using last observation on study or last observation prior to pioglitazone
rescue therapy for patients needing rescue.</td></tr>
<tr><td colspan="4">
<span class="Sup">â€ </span>Â Â Least
squares mean adjusted for baseline value.</td></tr>
<tr><td colspan="4">
<span class="Sup">â€¡</span>Â Â p-value
&lt;0.0001 compared to placebo + metformin</td></tr>
<tr class="Last"><td colspan="4">
<span class="Sup">Â§</span>Â Â p-value
&lt;0.05 compared to placebo + metformin</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule"><span class="Bold">Hemoglobin A1C (%)</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=186</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=186</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=175</span></td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Baseline (mean)</td>
<td class="Lrule Rrule" align="center">8.1</td>
<td class="Lrule Rrule" align="center">8.1</td>
<td class="Lrule Rrule" align="center">8.1</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Change from
baseline (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’0.6</td>
<td class="Lrule Rrule" align="center">âˆ’0.7</td>
<td class="Lrule Rrule" align="center">+0.1</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Difference
from placebo (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’0.7<span class="Sup">â€¡</span>
</td>
<td class="Lrule Rrule" align="center">âˆ’0.8<span class="Sup">â€¡</span>
</td>
<td class="Lrule Rrule" align="center">Â </td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Â Â 95%
Confidence Interval</td>
<td class="Lrule Rrule" align="center">(âˆ’0.9, âˆ’0.5)</td>
<td class="Lrule Rrule" align="center">(âˆ’1.0, âˆ’0.6)</td>
<td class="Lrule Rrule" align="center">Â </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Percent
of patients achieving A1C &lt;7%</td>
<td class="Botrule Lrule Rrule" align="center">37%<span class="Sup">Â§</span> (69/186)</td>
<td class="Botrule Lrule Rrule" align="center">44%<span class="Sup">Â§</span> (81/186)</td>
<td class="Botrule Lrule Rrule" align="center">17% (29/175)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"><span class="Bold">Fasting Plasma Glucose (mg/dL)</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=188</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=187</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=176</span></td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Baseline (mean)</td>
<td class="Lrule Rrule" align="center">174</td>
<td class="Lrule Rrule" align="center">179</td>
<td class="Lrule Rrule" align="center">175</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Change from
baseline (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’14</td>
<td class="Lrule Rrule" align="center">âˆ’22</td>
<td class="Lrule Rrule" align="center">+1</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Difference
from placebo (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’16<span class="Sup">Â§</span>
</td>
<td class="Lrule Rrule" align="center">âˆ’23<span class="Sup">Â§</span>
</td>
<td class="Lrule Rrule" align="center">Â </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â 95%
Confidence Interval</td>
<td class="Botrule Lrule Rrule" align="center">(âˆ’23, âˆ’9)</td>
<td class="Botrule Lrule Rrule" align="center">(âˆ’30, âˆ’16)</td>
<td class="Botrule Lrule Rrule" align="center">Â </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"><span class="Bold">2-hour Postprandial Glucose (mg/dL)</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=155</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=155</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=135</span></td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Baseline (mean)</td>
<td class="Lrule Rrule" align="center">294</td>
<td class="Lrule Rrule" align="center">296</td>
<td class="Lrule Rrule" align="center">295</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Change from
baseline (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’62</td>
<td class="Lrule Rrule" align="center">âˆ’58</td>
<td class="Lrule Rrule" align="center">âˆ’18</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Difference
from placebo (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’44<span class="Sup">Â§</span>
</td>
<td class="Lrule Rrule" align="center">âˆ’40<span class="Sup">Â§</span>
</td>
<td class="Lrule Rrule" align="center">Â </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule">Â Â Â Â 95%
Confidence Interval</td>
<td class="Botrule Lrule Rrule" align="center">(âˆ’60, âˆ’27)</td>
<td class="Botrule Lrule Rrule" align="center">(âˆ’56, âˆ’24)</td>
<td class="Botrule Lrule Rrule" align="center">Â </td>
</tr>
</tbody>
</table>
<a name="ibf13934b-6ef1-47ae-8543-89466fbca07f"></a><table border="0" cellpadding="2" cellspacing="1">
<caption><span>Figure 1: Mean Change from Baseline in A1C in a Placebo-Controlled
Trial of ONGLYZA as Add-On Combination Therapy with Metformin*</span></caption>
<colgroup><col></colgroup>
<tfoot><tr class="First Last" valign="middle"><td>*Â Â Includes patients with a baseline
and week 24 value.<br>Week 24 (LOCF) includes intent-to-treat population
using last observation on study prior to pioglitazone rescue 	therapy for
patients needing rescue. Mean change from baseline is adjusted for baseline
value.</td></tr></tfoot>
<tbody class="Headless"><tr class="First Last"><td><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d45fc842-2563-4421-86af-a55b3191e19b&amp;name=figure-1.jpg"></td></tr></tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14.2.2"></a><a name="section-13.2.2"></a><p></p>
<h3>Add-On Combination Therapy with a Thiazolidinedione</h3>
<p class="First">A total of 565 patients with type
2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> participated in this 24-week, randomized, double-blind, placebo-controlled
trial to evaluate the efficacy and safety of ONGLYZA in combination with a
thiazolidinedione (TZD) in patients with inadequate glycemic control (A1C
â‰¥7% to â‰¤10.5%) on TZD alone. To qualify for enrollment, patients were required
to be on a stable dose of pioglitazone (30-45 mg once daily) or rosiglitazone
(4 mg once daily or 8 mg either once daily or in two divided doses of 4 mg)
for at least 12 weeks.</p>
<p>Patients who met eligibility
criteria were enrolled in a single-blind, 2-week, dietary and exercise placebo
lead-in period during which patients received TZD at their pre-study dose. Following the lead-in period, eligible patients
were randomized to 2.5Â mg or 5 mg of ONGLYZA or placebo in
addition to their current dose of TZD. Patients who failed to meet specific
glycemic goals during the study were treated with metformin rescue, added
on to existing study medications. Dose titration of ONGLYZA or TZD was not
permitted during the study. A change in TZD regimen from rosiglitazone to
pioglitazone at specified, equivalent therapeutic doses was permitted at the
investigatorâ€™s discretion if believed to be medically appropriate.</p>
<p>ONGLYZA
2.5 mg and 5 mg add-on to TZD provided significant improvements in A1C, FPG,
and PPG compared with placebo add-on to TZD (Table 7). The proportion of patients
who discontinued for lack of glycemic control or who were rescued for meeting
prespecified glycemic criteria was 10% in the ONGLYZA 2.5 mg add-on to TZD
group, 6% for the ONGLYZA 5 mg add-on to TZD group, and 10% in the placebo
add-on to TZD group.</p>
<a name="i27e951f1-f525-4361-829c-64e5088aa254"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 7: Glycemic Parameters at Week 24 in a Placebo-Controlled Study
of ONGLYZA as Add-On Combination Therapy with a Thiazolidinedione*</span></caption>
<colgroup>
<col width="40%">
<col width="20%">
<col width="20%">
<col width="20%">
</colgroup>
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Efficacy
Parameter</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">ONGLYZA
2.5 mg<br>+<br>TZD<br>N=195</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">ONGLYZA
5 mg<br>+<br>TZD<br>N=186</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Placebo<br>+<br>TZD<br>N=184</span></th>
</tr></thead>
<tfoot>
<tr class="First"><td colspan="4">*Â Â Intent-to-treat population
using last observation on study or last observation prior to metformin rescue
therapy for patients needing rescue.</td></tr>
<tr><td colspan="4">
<span class="Sup">â€ </span>Â Â Least
squares mean adjusted for baseline value.</td></tr>
<tr><td colspan="4">
<span class="Sup">â€¡</span>Â Â p-value
&lt;0.0001 compared to placebo + TZD</td></tr>
<tr class="Last"><td colspan="4">
<span class="Sup">Â§</span>Â Â p-value
&lt;0.05 compared to placebo + TZD</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule"><span class="Bold">Hemoglobin A1C (%)</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=192</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=183</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=180</span></td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Baseline (mean)</td>
<td class="Lrule Rrule" align="center">8.3</td>
<td class="Lrule Rrule" align="center">8.4</td>
<td class="Lrule Rrule" align="center">8.2</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Change from
baseline (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’0.7</td>
<td class="Lrule Rrule" align="center">âˆ’0.9</td>
<td class="Lrule Rrule" align="center">âˆ’0.3</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Difference
from placebo (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’0.4<span class="Sup">Â§</span>
</td>
<td class="Lrule Rrule" align="center">âˆ’0.6<span class="Sup">â€¡</span>
</td>
<td class="Lrule Rrule" align="center">Â </td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Â Â 95%
Confidence Interval</td>
<td class="Lrule Rrule" align="center">(âˆ’0.6, âˆ’0.2)</td>
<td class="Lrule Rrule" align="center">(âˆ’0.8, âˆ’0.4)</td>
<td class="Lrule Rrule" align="center">Â </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Percent
of patients achieving A1C &lt;7%</td>
<td class="Botrule Lrule Rrule" align="center">42%<span class="Sup">Â§</span> (81/192)</td>
<td class="Botrule Lrule Rrule" align="center">42%<span class="Sup">Â§</span> (77/184)</td>
<td class="Botrule Lrule Rrule" align="center">26% (46/180)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"><span class="Bold">Fasting Plasma Glucose (mg/dL)</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=193</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=185</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=181</span></td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Baseline (mean)</td>
<td class="Lrule Rrule" align="center">163</td>
<td class="Lrule Rrule" align="center">160</td>
<td class="Lrule Rrule" align="center">162</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Change from
baseline (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’14</td>
<td class="Lrule Rrule" align="center">âˆ’17</td>
<td class="Lrule Rrule" align="center">âˆ’3</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Difference
from placebo (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’12<span class="Sup">Â§</span>
</td>
<td class="Lrule Rrule" align="center">âˆ’15<span class="Sup">Â§</span>
</td>
<td class="Lrule Rrule" align="center">Â </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â 95%
Confidence Interval</td>
<td class="Botrule Lrule Rrule" align="center">(âˆ’20, âˆ’3)</td>
<td class="Botrule Lrule Rrule" align="center">(âˆ’23, âˆ’6)</td>
<td class="Botrule Lrule Rrule" align="center">Â </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"><span class="Bold">2-hour Postprandial Glucose (mg/dL)</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=156</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=134</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=127</span></td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Baseline (mean)</td>
<td class="Lrule Rrule" align="center">296</td>
<td class="Lrule Rrule" align="center">303</td>
<td class="Lrule Rrule" align="center">291</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Change from
baseline (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’55</td>
<td class="Lrule Rrule" align="center">âˆ’65</td>
<td class="Lrule Rrule" align="center">âˆ’15</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Difference
from placebo (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’40<span class="Sup">Â§</span>
</td>
<td class="Lrule Rrule" align="center">âˆ’50<span class="Sup">Â§</span>
</td>
<td class="Lrule Rrule" align="center">Â </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule">Â Â Â Â 95%
Confidence Interval</td>
<td class="Botrule Lrule Rrule" align="center">(âˆ’56, âˆ’24)</td>
<td class="Botrule Lrule Rrule" align="center">(âˆ’66, âˆ’34)</td>
<td class="Botrule Lrule Rrule" align="center">Â </td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14.2.3"></a><a name="section-13.2.3"></a><p></p>
<h3>Add-On Combination Therapy with Glyburide</h3>
<p class="First">A total of 768 patients with type
2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> participated in this 24-week, randomized, double-blind, placebo-controlled
trial to evaluate the efficacy and safety of ONGLYZA in combination with a
sulfonylurea (SU) in patients with inadequate glycemic control at enrollment
(A1C â‰¥7.5% to â‰¤10%) on a submaximal dose of SU alone. To qualify for enrollment,
patients were required to be on a submaximal dose of SU for 2 months or greater.
In this study, ONGLYZA in combination with a fixed, intermediate dose of SU
was compared to titration to a higher dose of SU.</p>
<p>Patients
who met eligibility criteria were enrolled in a single-blind, 4-week, dietary
and exercise lead-in period, and placed on glyburide 7.5 mg once daily. Following
the lead-in period, eligible patients with A1C â‰¥7% to â‰¤10% were randomized
to either 2.5 mg or 5 mg of ONGLYZA add-on to 7.5 mg glyburide or to placebo
plus a 10 mg total daily dose of glyburide. Patients who received placebo
were eligible to have glyburide up-titrated to a total daily dose of 15 mg.
Up-titration of glyburide was not permitted in patients who received ONGLYZA
2.5 mg or 5 mg. Glyburide could be down-titrated in any treatment group once
during the 24-week study period due to <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> as deemed necessary by
the investigator. Approximately 92% of patients in the placebo plus glyburide
group were up-titrated to a final total daily dose of 15 mg during the first
4 weeks of the study period. Patients who failed to meet specific glycemic
goals during the study were treated with metformin rescue, added on to existing
study medication. Dose titration of ONGLYZA was not permitted during the study. </p>
<p>In
combination with glyburide, ONGLYZA 2.5 mg and 5 mg provided significant improvements
in A1C, FPG, and PPG compared with the placebo plus up-titrated glyburide
group (Table 8). The proportion of patients who discontinued for lack of glycemic
control or who were rescued for meeting prespecified glycemic criteria was
18% in the ONGLYZA 2.5 mg add-on to glyburide group, 17% in the ONGLYZA 5
mg add-on to glyburide group, and 30% in the placebo plus up-titrated glyburide
group.</p>
<a name="ia1e8d550-2f25-4a11-8c2d-3c66e7bd19f5"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 8: Glycemic Parameters at Week 24 in a Placebo-Controlled Study
of ONGLYZA as Add-On Combination Therapy with Glyburide*</span></caption>
<colgroup>
<col width="40%">
<col width="20%">
<col width="20%">
<col width="20%">
</colgroup>
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Efficacy
Parameter</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">ONGLYZA<br>2.5
mg<br>+ <br>Glyburide<br>7.5 mg<br>N=248</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">ONGLYZA<br>5
mg<br>+ <br>Glyburide<br>7.5 mg<br>N=253</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Placebo<br><br>+ <br>Up-Titrated
Glyburide<br>N=267</span></th>
</tr></thead>
<tfoot>
<tr class="First"><td colspan="4">*Â Â Intent-to-treat population
using last observation on study or last observation prior to metformin rescue
therapy for patients needing rescue.</td></tr>
<tr><td colspan="4">
<span class="Sup">â€ </span>Â Â Least
squares mean adjusted for baseline value.</td></tr>
<tr><td colspan="4">
<span class="Sup">â€¡</span>Â Â p-value
&lt;0.0001 compared to placebo + up-titrated glyburide</td></tr>
<tr class="Last"><td colspan="4">
<span class="Sup">Â§</span>Â Â p-value
&lt;0.05 compared to placebo + up-titrated glyburide</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule"><span class="Bold">Hemoglobin A1C (%)</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=246</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=250</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=264</span></td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Baseline (mean)</td>
<td class="Lrule Rrule" align="center">8.4</td>
<td class="Lrule Rrule" align="center">8.5</td>
<td class="Lrule Rrule" align="center">8.4</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Change from
baseline (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’0.5</td>
<td class="Lrule Rrule" align="center">âˆ’0.6</td>
<td class="Lrule Rrule" align="center">+0.1</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Difference
from up-titrated glyburide (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’0.6<span class="Sup">â€¡</span>
</td>
<td class="Lrule Rrule" align="center">âˆ’0.7<span class="Sup">â€¡</span>
</td>
<td class="Lrule Rrule" align="center">Â </td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Â Â 95%
Confidence Interval</td>
<td class="Lrule Rrule" align="center">(âˆ’0.8, âˆ’0.5)</td>
<td class="Lrule Rrule" align="center">(âˆ’0.9, âˆ’0.6)</td>
<td class="Lrule Rrule" align="center">Â </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Percent
of patients achieving A1C &lt;7%</td>
<td class="Botrule Lrule Rrule" align="center">22%<span class="Sup">Â§</span> (55/246)</td>
<td class="Botrule Lrule Rrule" align="center">23%<span class="Sup">Â§</span> (57/250)</td>
<td class="Botrule Lrule Rrule" align="center">9% (24/264)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"><span class="Bold">Fasting Plasma Glucose (mg/dL)</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=247</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=252</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=265</span></td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Baseline (mean)</td>
<td class="Lrule Rrule" align="center">170</td>
<td class="Lrule Rrule" align="center">175</td>
<td class="Lrule Rrule" align="center">174</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Change from
baseline (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’7</td>
<td class="Lrule Rrule" align="center">âˆ’10</td>
<td class="Lrule Rrule" align="center">+1</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Difference
from up-titrated glyburide (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’8<span class="Sup">Â§</span>
</td>
<td class="Lrule Rrule" align="center">âˆ’10<span class="Sup">Â§</span>
</td>
<td class="Lrule Rrule" align="center">Â </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â 95%
Confidence Interval</td>
<td class="Botrule Lrule Rrule" align="center">(âˆ’14, âˆ’1)</td>
<td class="Botrule Lrule Rrule" align="center">(âˆ’17, âˆ’4)</td>
<td class="Botrule Lrule Rrule" align="center">Â </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"><span class="Bold">2-hour Postprandial Glucose (mg/dL)</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=195</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=202</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=206</span></td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Baseline (mean)</td>
<td class="Lrule Rrule" align="center">309</td>
<td class="Lrule Rrule" align="center">315</td>
<td class="Lrule Rrule" align="center">323</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Change from
baseline (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’31</td>
<td class="Lrule Rrule" align="center">âˆ’34</td>
<td class="Lrule Rrule" align="center">+8</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Difference
from up-titrated glyburide (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’38<span class="Sup">Â§</span>
</td>
<td class="Lrule Rrule" align="center">âˆ’42<span class="Sup">Â§</span>
</td>
<td class="Lrule Rrule" align="center">Â </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule">Â Â Â Â 95%
Confidence Interval</td>
<td class="Botrule Lrule Rrule" align="center">(âˆ’50, âˆ’27)</td>
<td class="Botrule Lrule Rrule" align="center">(âˆ’53, âˆ’31)</td>
<td class="Botrule Lrule Rrule" align="center">Â </td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14.2.4"></a><a name="section-13.2.4"></a><p></p>
<h3>Coadministration with Metformin in Treatment-Naive Patients</h3>
<p class="First">A total of 1306 treatment-naive patients
with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus participated in this 24-week, randomized, double-blind,
active-controlled trial to evaluate the efficacy and safety of ONGLYZA coadministered
with metformin in patients with inadequate glycemic control (A1C â‰¥8% to â‰¤12%)
on diet and exercise alone. Patients were required to be treatment-naive to
be enrolled in this study. </p>
<p>Patients who met eligibility
criteria were enrolled in a single-blind, 1-week, dietary and exercise placebo
lead-in period. Patients were randomized to one of four treatment arms: ONGLYZA
5 mg + metformin 500 mg, saxagliptin 10 mg + metformin 500 mg, saxagliptin
10 mg + placebo, or metformin 500 mg + placebo. ONGLYZA was dosed once daily.
In the 3 treatment groups using metformin, the metformin dose was up-titrated
weekly in 500 mg per day increments, as tolerated, to a maximum of 2000 mg
per day based on FPG. Patients who failed to meet specific glycemic goals
during the studies were treated with pioglitazone rescue as add-on therapy. </p>
<p>Coadministration
of ONGLYZA 5 mg plus metformin provided significant improvements in A1C, FPG,
and PPG compared with placebo plus metformin (Table 9).</p>
<a name="i3aebfd61-a126-48c7-80e4-377ae3671915"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 9: Glycemic Parameters at Week 24 in a Placebo-Controlled Trial
of ONGLYZA Coadministration with Metformin in Treatment-Naive Patients*</span></caption>
<colgroup>
<col width="50%">
<col width="25%">
<col width="25%">
</colgroup>
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Efficacy
Parameter</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">ONGLYZA
5 mg<br>+ <br>Metformin<br>N=320</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Placebo<br>+<br>Metformin<br>N=328</span></th>
</tr></thead>
<tfoot>
<tr class="First"><td colspan="3">*Â Â Intent-to-treat population
using last observation on study or last observation prior to pioglitazone
rescue therapy for patients needing rescue.</td></tr>
<tr><td colspan="3">
<span class="Sup">â€ </span>Â Â Least
squares mean adjusted for baseline value.</td></tr>
<tr><td colspan="3">
<span class="Sup">â€¡</span>Â Â p-value
&lt;0.0001 compared to placebo + metformin</td></tr>
<tr class="Last"><td colspan="3">
<span class="Sup">Â§</span>Â Â p-value
&lt;0.05 compared to placebo + metformin</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule"><span class="Bold">Hemoglobin A1C (%)</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=306</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=313</span></td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Baseline (mean)</td>
<td class="Lrule Rrule" align="center">9.4</td>
<td class="Lrule Rrule" align="center">9.4</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Change from
baseline (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’2.5</td>
<td class="Lrule Rrule" align="center">âˆ’2.0</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Difference
from placebo + metformin (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’0.5<span class="Sup">â€¡</span>
</td>
<td class="Lrule Rrule" align="center">Â </td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Â Â 95%
Confidence Interval</td>
<td class="Lrule Rrule" align="center">(âˆ’0.7, âˆ’0.4)</td>
<td class="Lrule Rrule" align="center">Â </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Percent
of patients achieving A1C &lt;7%</td>
<td class="Botrule Lrule Rrule" align="center">60%<span class="Sup">Â§</span> (185/307)</td>
<td class="Botrule Lrule Rrule" align="center">41% (129/314)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"><span class="Bold">Fasting Plasma Glucose (mg/dL)</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=315</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=320</span></td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Baseline (mean)</td>
<td class="Lrule Rrule" align="center">199</td>
<td class="Lrule Rrule" align="center">199</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Change from
baseline (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’60</td>
<td class="Lrule Rrule" align="center">âˆ’47</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Difference
from placebo + metformin (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’13<span class="Sup">Â§</span>
</td>
<td class="Lrule Rrule" align="center">Â </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â 95%
Confidence Interval</td>
<td class="Botrule Lrule Rrule" align="center">(âˆ’19, âˆ’6)</td>
<td class="Botrule Lrule Rrule" align="center">Â </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"><span class="Bold">2-hour Postprandial Glucose (mg/dL)</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=146</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=141</span></td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Baseline (mean)</td>
<td class="Lrule Rrule" align="center">340</td>
<td class="Lrule Rrule" align="center">355</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Change from
baseline (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’138</td>
<td class="Lrule Rrule" align="center">âˆ’97</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Difference
from placebo + metformin (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’41<span class="Sup">Â§</span>
</td>
<td class="Lrule Rrule" align="center">Â </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule">Â Â Â Â 95%
Confidence Interval</td>
<td class="Botrule Lrule Rrule" align="center">(âˆ’57, âˆ’25)</td>
<td class="Botrule Lrule Rrule" align="center">Â </td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14.2.5"></a><a name="section-13.2.5"></a><p></p>
<h3>Add-On Combination Therapy with Metformin versus Glipizide Add-On Combination Therapy with Metformin</h3>
<p class="First">In this 52-week, active-controlled trial, a total of 858 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and inadequate glycemic control (A1C &gt;6.5% and â‰¤10%) on metformin alone were randomized to double-blind add-on therapy with ONGLYZA or glipizide. Patients were required to be on a stable dose of metformin (at least 1500 mg daily) for at least 8 weeks prior to enrollment.</p>
<p>Patients who met eligibility criteria were enrolled in a single-blind, 2-week, dietary and exercise placebo lead-in period during which patients received metformin (1500-3000 mg based on their pre-study dose). Following the lead-in period, eligible patients were randomized to 5 mg of ONGLYZA or 5 mg of glipizide in addition to their current dose of open-label metformin. Patients in the glipizide plus metformin group underwent blinded titration of the glipizide dose during the first 18 weeks of the trial up to a maximum glipizide dose of 20 mg per day. Titration was based on a goal FPG â‰¤110 mg/dL or the highest tolerable glipizide dose. Fifty percent (50%) of the glipizide-treated patients were titrated to the 20-mg daily dose; 21% of the glipizide-treated patients had a final daily glipizide dose of 5 mg or less. The mean final daily dose of glipizide was 15 mg.</p>
<p>After 52 weeks of treatment, ONGLYZA and glipizide resulted in similar mean reductions from baseline in A1C when added to metformin therapy (Table 10). This conclusion may be limited to patients with baseline A1C comparable to those in the trial (91% of patients had baseline A1C &lt;9%).</p>
<p>From a baseline mean body weight of 89 kg, there was a statistically significant mean reduction of 1.1 kg in patients treated with ONGLYZA compared to a mean <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> of 1.1 kg in patients treated with glipizide (p&lt;0.0001).</p>
<a name="i99b7f6b9-805f-4dea-8e2a-7e95afa1ba1a"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 10: Glycemic Parameters at Week 52 in an Active-Controlled Trial of ONGLYZA versus Glipizide in Combination with Metformin*</span></caption>
<colgroup>
<col width="50%">
<col width="25%">
<col width="25%">
</colgroup>
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Efficacy Parameter</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">ONGLYZA 5 mg<br>+ <br>Metformin<br>N=428</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Titrated Glipizide <br>+<br>Metformin<br>N=430</span></th>
</tr></thead>
<tfoot>
<tr class="First"><td colspan="3">*Â Â Intent-to-treat population using last observation on study.</td></tr>
<tr><td colspan="3">
<span class="Sup">â€ </span>Â Â Least squares mean adjusted for baseline value.</td></tr>
<tr><td colspan="3">
<span class="Sup">â€¡</span>Â Â Saxagliptin + metformin is considered non-inferior to glipizide + metformin because the upper limit of this confidence interval is less than the prespecified non-inferiority margin of 0.35%.</td></tr>
<tr class="Last"><td colspan="3">
<span class="Sup">Â§</span>Â Â Significance not tested.</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule"><span class="Bold">Hemoglobin A1C (%)</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=423</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=423</span></td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Baseline (mean)</td>
<td class="Lrule Rrule" align="center">7.7</td>
<td class="Lrule Rrule" align="center">7.6</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Change from baseline (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’0.6</td>
<td class="Lrule Rrule" align="center">âˆ’0.7</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Difference from glipizide + metformin (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">0.1
													</td>
<td class="Lrule Rrule" align="center">Â </td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Â Â 95% Confidence Interval</td>
<td class="Lrule Rrule" align="center">(âˆ’0.02, 0.2)<span class="Sup">â€¡</span>
</td>
<td class="Lrule Rrule" align="center">Â </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"><span class="Bold">Fasting Plasma Glucose (mg/dL)</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=420</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=420</span></td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Baseline (mean)</td>
<td class="Lrule Rrule" align="center">162</td>
<td class="Lrule Rrule" align="center">161</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Change from baseline (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’9</td>
<td class="Lrule Rrule" align="center">âˆ’16</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Difference from glipizide + metformin (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">6	</td>
<td class="Lrule Rrule" align="center">Â </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule">Â Â Â Â 95% Confidence Interval</td>
<td class="Botrule Lrule Rrule" align="center">(2, 11)<span class="Sup">Â§</span>
</td>
<td class="Botrule Lrule Rrule" align="center">Â </td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14.2.6"></a><a name="section-13.2.6"></a><p></p>
<h3>Add-On Combination Therapy with Insulin (with or without metformin)</h3>
<p class="First">A total of 455 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> participated in this 24-week, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of ONGLYZA in combination with insulin in patients with inadequate glycemic control (A1C â‰¥7.5% and â‰¤11%) on insulin alone (N=141) or on insulin in combination with a stable dose of metformin (N=314). Patients were required to be on a stable dose of insulin (â‰¥30 units to â‰¤150 units daily) with â‰¤20% variation in total daily dose for â‰¥8 weeks prior to screening. Patients entered the trial on intermediate- or long-acting (basal) insulin or premixed insulin. Patients using short-acting insulins were excluded unless the short-acting insulin was administered as part of a premixed insulin.</p>
<p>Patients who met eligibility criteria were enrolled in a single-blind, four-week, dietary and exercise placebo lead-in period during which patients received insulin (and metformin if applicable) at their pretrial dose(s). Following the lead-in period, eligible patients were randomized to add-on therapy with either ONGLYZA 5 mg or placebo. Doses of the antidiabetic therapies were to remain stable but patients were rescued and allowed to adjust the insulin regimen if specific glycemic goals were not met or if the investigator learned that the patient had self-increased the insulin dose by &gt;20%. Data after rescue were excluded from the primary efficacy analyses.</p>
<p>Add-on therapy with ONGLYZA 5 mg provided significant improvements from baseline to Week 24 in A1C and PPG compared with add-on placebo (Table 11). Similar mean reductions in A1C versus placebo were observed for patients using ONGLYZA 5 mg add-on to insulin alone and ONGLYZA 5 mg add-on to insulin in combination with metformin (âˆ’0.4% and âˆ’0.4%, respectively). The percentage of patients who discontinued for lack of glycemic control or who were rescued was 23% in the ONGLYZA group and 32% in the placebo group.</p>
<p>The mean daily insulin dose at baseline was 53 units in patients treated with ONGLYZA 5 mg and 55 units in patients treated with placebo. The mean change from baseline in daily dose of insulin was 2 units for the ONGLYZA 5 mg group and 5 units for the placebo group.</p>
<a name="i3d5ab8b0-c753-49fa-850b-23831081a9cb"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 11: Glycemic Parameters at Week 24 in a Placebo-Controlled Trial of ONGLYZA as Add-On Combination Therapy with Insulin*</span></caption>
<colgroup>
<col width="50%">
<col width="25%">
<col width="25%">
</colgroup>
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Efficacy
Parameter</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">ONGLYZA
5 mg<br>+ <br>Insulin<br>(+/âˆ’ Metformin)<br>N=304</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Placebo<br>+<br>Insulin<br>(+/âˆ’ Metformin)<br>N=151</span></th>
</tr></thead>
<tfoot>
<tr class="First"><td colspan="3">*Â Â Intent-to-treat population using last observation on study or last observation prior to insulin rescue therapy for patients needing rescue.</td></tr>
<tr><td colspan="3">
<span class="Sup">â€ </span>Â Â Least squares mean adjusted for baseline value and metformin use at baseline.</td></tr>
<tr><td colspan="3">
<span class="Sup">â€¡</span>Â Â p-value
&lt;0.0001 compared to placebo + insulin</td></tr>
<tr class="Last"><td colspan="3">
<span class="Sup">Â§</span>Â Â p-value &lt;0.05 compared to placebo + insulin</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule"><span class="Bold">Hemoglobin A1C (%)</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=300</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=149</span></td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Baseline (mean)</td>
<td class="Lrule Rrule" align="center">8.7</td>
<td class="Lrule Rrule" align="center">8.7</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Change from
baseline (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’0.7</td>
<td class="Lrule Rrule" align="center">âˆ’0.3</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Difference
from placebo (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’0.4<span class="Sup">â€¡</span>
</td>
<td class="Lrule Rrule" align="center">Â </td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Â Â 95%
Confidence Interval</td>
<td class="Lrule Rrule" align="center">(âˆ’0.6, âˆ’0.2)</td>
<td class="Lrule Rrule" align="center">Â </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Percent
of patients achieving A1C &lt;7%</td>
<td class="Botrule Lrule Rrule" align="center">17% (52/300)</td>
<td class="Botrule Lrule Rrule" align="center">7% (10/149)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"><span class="Bold">Fasting Plasma Glucose (mg/dL)</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=300</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=149</span></td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Baseline (mean)</td>
<td class="Lrule Rrule" align="center">173</td>
<td class="Lrule Rrule" align="center">173</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Change from
baseline (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’10</td>
<td class="Lrule Rrule" align="center">âˆ’6</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Difference
from placebo (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’4
													</td>
<td class="Lrule Rrule" align="center">Â </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â 95%
Confidence Interval</td>
<td class="Botrule Lrule Rrule" align="center">(âˆ’13, 5)</td>
<td class="Botrule Lrule Rrule" align="center">Â </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"><span class="Bold">2-hour Postprandial Glucose (mg/dL)</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=262</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=129</span></td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Baseline (mean)</td>
<td class="Lrule Rrule" align="center">251</td>
<td class="Lrule Rrule" align="center">255</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Change from
baseline (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’27</td>
<td class="Lrule Rrule" align="center">âˆ’4</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Difference
from placebo (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’23<span class="Sup">Â§</span>
</td>
<td class="Lrule Rrule" align="center">Â </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule">Â Â Â Â 95%
Confidence Interval</td>
<td class="Botrule Lrule Rrule" align="center">(âˆ’37, âˆ’9)</td>
<td class="Botrule Lrule Rrule" align="center">Â </td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14.3"></a><a name="section-13.3"></a><p></p>
<h2>14.3 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">A total of 170 patients participated in a 12-week, randomized, double-blind, placebo-controlled trial conducted to evaluate the efficacy and safety of ONGLYZA 2.5 mg once daily compared with placebo in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and moderate (n=90) or severe (n=41) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or ESRD (n=39). In this trial, 98% of the patients were using background antidiabetic medications (75% were using insulin and 31% were using oral antidiabetic medications, mostly sulfonylureas).</p>
<p>After 12 weeks of treatment, ONGLYZA 2.5 mg provided significant improvement in A1C compared to placebo (Table 12). In the subgroup of patients with ESRD, ONGLYZA and placebo resulted in comparable reductions in A1C from baseline to Week 12. This finding is inconclusive because the trial was not adequately powered to show efficacy within specific subgroups of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p>After 12 weeks of treatment, the mean change in FPG was âˆ’12 mg/dL with ONGLYZA 2.5 mg and âˆ’13 mg/dL with placebo. Compared to placebo, the mean change in FPG with ONGLYZA was âˆ’12 mg/dL in the subgroup of patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, âˆ’4 mg/dL in the subgroup of patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, and +44 mg/dL in the subgroup of patients with ESRD. These findings are inconclusive because the trial was not adequately powered to show efficacy within specific subgroups of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<a name="i8249d432-f380-443e-8de0-5733504381ec"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 12: A1C at Week 12 in a Placebo-Controlled Trial of ONGLYZA in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>*</span></caption>
<colgroup>
<col width="50%">
<col width="25%">
<col width="25%">
</colgroup>
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Efficacy Parameter</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">ONGLYZA 2.5 mg<br>N=85</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Placebo<br>N=85</span></th>
</tr></thead>
<tfoot>
<tr class="First"><td colspan="3">*Â Â Intent-to-treat population using last observation on study.</td></tr>
<tr><td colspan="3">
<span class="Sup">â€ </span>Â Â Least squares mean adjusted for baseline value.</td></tr>
<tr class="Last"><td colspan="3">
<span class="Sup">â€¡</span>Â Â p-value &lt;0.01 compared to placebo</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule"><span class="Bold">Hemoglobin A1C (%)</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=81</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">N=83</span></td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Baseline (mean)</td>
<td class="Lrule Rrule" align="center">8.4</td>
<td class="Lrule Rrule" align="center">8.1</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Change from baseline (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’0.9</td>
<td class="Lrule Rrule" align="center">âˆ’0.4</td>
</tr>
<tr>
<td class="Lrule Rrule">Â Â Difference from placebo (adjusted mean<span class="Sup">â€ </span>)</td>
<td class="Lrule Rrule" align="center">âˆ’0.4<span class="Sup">â€¡</span>
</td>
<td class="Lrule Rrule" align="center">Â </td>
</tr>
<tr class="Last">
<td class="Lrule Rrule">Â Â Â Â 95% Confidence Interval</td>
<td class="Lrule Rrule" align="center">(âˆ’0.7, âˆ’0.1)</td>
<td class="Lrule Rrule" align="center">Â </td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="34069-5">
<a name="s16.1"></a><a name="section-14.1"></a><p></p>
<div class="Section" data-sectionCode="34069-5">
<a name="s16.1.2"></a><a name="section-14.1.1"></a><p></p>
<h3>How Supplied</h3>
<p class="First">ONGLYZA<span class="Sup">Â®</span> (saxagliptin) tablets have markings
on both sides and are available in the strengths and packages listed in Table 12.</p>
<a name="i674ac364-97d6-4340-86eb-d7033607070d"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 12: ONGLYZA Tablet Presentations</span></caption>
<colgroup>
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
</colgroup>
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Tablet <br>Strength</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Film-Coated Tablet<br>Color/Shape</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Tablet <br>Markings</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Package Size</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">NDC Code</span></th>
</tr></thead>
<tbody><tr class="First Last">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="1" valign="top"><span class="Bold">5 mg</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top">pink<br>biconvex,
round</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">â€œ5â€? on one side
and â€œ4215â€? on the reverse, in blue ink</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">Bottles of 30</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">54868-6309-0</td>
</tr></tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="s16.2"></a><a name="section-14.2"></a><p></p>
<div class="Section" data-sectionCode="44425-7">
<a name="s16.2.1"></a><a name="section-14.2.1"></a><p></p>
<h3>Storage and Handling</h3>
<p class="First">Store at 20Â°-25Â°C (68Â°-77Â°F); excursions
permitted to 15Â°-30Â°C (59Â°-86Â°F) [see USP Controlled Room Temperature].</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s17"></a><a name="section-15"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-approved Medication Guide.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s17.1"></a><a name="section-15.1"></a><p></p>
<h2>17.1  Instructions</h2>
<p class="First"> Patients should be informed of the
potential risks and benefits of ONGLYZA and of alternative modes of therapy.
Patients should also be informed about the importance of adherence to dietary
instructions, regular physical activity, periodic blood glucose monitoring
and A1C testing, recognition and management of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>,
and assessment of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> complications. During periods of stress such as
<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, or surgery, medication requirements may change and
patients should be advised to seek medical advice promptly.</p>
<p>Patients should be informed that <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span> has been reported during postmarketing use of ONGLYZA. Before initiating ONGLYZA, patients should be questioned about other risk factors for <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, such as a history of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span>, <span class="product-label-link" type="condition" conceptid="196456" conceptname="Gallstone">gallstones</span>, or <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>. Patients should also be informed that persistent severe <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, sometimes radiating to the back, which may or may not be accompanied by <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, is the hallmark symptom of <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span>. Patients should be instructed to promptly discontinue ONGLYZA and contact their healthcare provider if persistent severe <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> occurs [see <span class="Italics"><a href="http://s5.1'">Warnings and Precautions (5.1)</a></span>].</p>
<p>Patients should be informed that serious allergic (<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>) reactions, such as <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, and exfoliative skin conditions, have been reported during postmarketing use of ONGLYZA. If symptoms of these <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> (such as <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, skin flaking or <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the skin, or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing) occur, patients must stop taking ONGLYZA and seek medical advice promptly.</p>
<p>Patients should be informed that if they miss a dose of ONGLYZA they should take the next dose as prescribed, unless otherwise instructed by their healthcare provider. Patients should be instructed not to take an extra dose the next day.</p>
<p>Healthcare providers should instruct their patients to read the Medication Guide before starting ONGLYZA therapy and to reread it each time the prescription is renewed. Patients should be instructed to inform their healthcare provider if they develop any unusual symptom or if any existing symptom persists or worsens.</p>
<p>Patients should be informed that ONGLYZA tablets must not be split or cut.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="s17.2"></a><a name="section-15.2"></a><p></p>
<h2>17.2  Laboratory Tests</h2>
<p class="First"> Patients should be informed that
response to all diabetic therapies should be monitored by periodic measurements
of blood glucose and A1C, with a goal of decreasing these levels toward the
normal range. A1C is especially useful for evaluating long-term glycemic control.
Patients should be informed of the potential need to adjust their dose based
on changes in renal function tests over time.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="eSign"></a><a name="section-16"></a><p></p>
<p class="First"><br><br>Manufactured by:<br>Bristol-Myers
Squibb Company<br> Princeton, NJ 08543 USA</p>
<p>Marketed
by:<br>Bristol-Myers Squibb Company<br> Princeton, NJ 08543<br>and<br>AstraZeneca
Pharmaceuticals LP<br>Wilmington, DE 19850</p>
<p>1297954 / 1256314A3<br>Rev December 2011</p>
<br><br><br><br><br><br><div class="Section" data-sectionCode="42229-5">
<a name="section-16.1"></a><p></p>
<p class="First"><span class="Bold">Additional barcode labeling by:</span><br>Physicians Total Care, Inc.<br>Tulsa, OklahomaÂ Â Â Â Â  74146<br></p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="s18"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">MEDICATION GUIDE<br>ONGLYZA (on-GLY-zah)<br>(saxagliptin)<br>tablets</span></p>
<p>Read this Medication Guide carefully before you start taking ONGLYZA and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or treatment. If you have any questions about ONGLYZA, ask your healthcare provider.</p>
<p><span class="Bold">What is the most important information I should know about ONGLYZA?</span></p>
<p><span class="Bold">Serious side effects can happen to people taking ONGLYZA</span>, including <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the pancreas (<span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>) which may be severe and lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>Certain medical problems make you more likely to get <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</p>
<p><span class="Bold">Before you start taking ONGLYZA:</span></p>
<p>Tell your healthcare provider if you have ever had</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of your pancreas (<span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>)</li>
<li>stones in your gallbladder (<span class="product-label-link" type="condition" conceptid="196456" conceptname="Gallstone">gallstones</span>)</li>
<li>a history of <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span></li>
<li>high blood triglyceride levels</li>
</ul>
<p>It is not known if having these medical problems will make you more likely to get <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> with ONGLYZA.</p>
<p>Stop taking ONGLYZA and contact your healthcare provider right away if you have <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your stomach area (abdomen) that is severe and will not go away. The <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> may be felt going from your abdomen through to your back. The <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> may happen with or without <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. These may be symptoms of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</p>
<p><span class="Bold">What is ONGLYZA?</span></p>
<ul class="Disc">
<li>ONGLYZA
is a prescription medicine used with diet and exercise to control high blood
sugar (<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>) in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</li>
<li>ONGLYZA
lowers blood sugar by helping the body increase the level of insulin after
meals.</li>
<li>ONGLYZA is unlikely by itself to cause your blood sugar
to be lowered to a dangerous level (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>) because it does not work
well when your blood sugar is low.  However, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> may still occur with ONGLYZA. Your risk for getting <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> is higher if you take ONGLYZA with some other <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicines, such as a sulfonylurea or insulin.</li>
<li>ONGLYZA is not for people with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</li>
<li>ONGLYZA is not for people with <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span> (increased <span class="product-label-link" type="condition" conceptid="4017413" conceptname="Acetoacetate">ketones</span> in your blood or urine).</li>
<li>If you have had <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> in the past, it is not known if you have a higher chance of getting <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> while you take ONGLYZA.</li>
</ul>
<p>It is not known if ONGLYZA is safe and effective in children younger than 18 years old.</p>
<p><span class="Bold">Who should not take ONGLYZA?</span></p>
<p><span class="Bold">Do not take ONGLYZA if you:</span></p>
<ul class="Disc"><li>are allergic to any ingredients in ONGLYZA. See the end of this Medication Guide for a complete list of ingredients in ONGLYZA.</li></ul>
<dl class="Disc">
<dt>Â </dt>
<dd>Symptoms of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to ONGLYZA may include:
								<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, lips, throat, and other areas on your skin</li>
<li>difficulty with swallowing or breathing</li>
<li>raised, red areas on your skin (<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, flaking, or <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span></li>
</ul>
</dd>
</dl>
<dl class="Disc">
<dt>Â </dt>
<dd>If you have these symptoms, stop taking ONGLYZA and contact your healthcare provider right away.
						</dd>
</dl>
<p><span class="Bold">What should I tell my healthcare provider
before taking ONGLYZA?</span></p>
<p><span class="Bold">Before you take ONGLYZA, tell your healthcare provider if you:</span></p>
<ul class="Disc">
<li>have kidney problems.</li>
<li>are pregnant or plan to become pregnant. It is not known if ONGLYZA
will harm your unborn baby. If you are pregnant, talk with your healthcare
provider about the best way to control your blood sugar while you are pregnant.</li>
<li>are breast-feeding or plan to breast-feed. ONGLYZA may be passed
in your milk to your baby. Talk with your healthcare provider about the best
way to feed your baby while you take ONGLYZA.</li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all the medicines
you take</span>, including prescription and nonprescription medicines, vitamins,
and herbal supplements.</p>
<p>Know the medicines you take. Keep a list of your medicines
and show it to your healthcare provider and pharmacist when you get a new
medicine.</p>
<p>ONGLYZA may affect the way other medicines
work, and other medicines may affect how ONGLYZA works. Contact your healthcare
provider if you will be starting or stopping certain other types of medications,
such as antibiotics, or medicines that treat fungus or HIV/AIDS, because your
dose of ONGLYZA might need to be changed.</p>
<p><span class="Bold">How should I take ONGLYZA?</span></p>
<ul class="Disc">
<li>Take ONGLYZA by mouth one time each day exactly as directed by your
healthcare provider. Do not change your dose without talking to your healthcare
provider.</li>
<li>ONGLYZA can be taken with or without food.</li>
<li>Do not split or cut ONGLYZA tablets.</li>
<li>During periods of stress on the body, such as:<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li><span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span></li>
<li><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></li>
<li>surgery</li>
</ul>
</li>
</ul>
<dl class="Disc">
<dt>Â </dt>
<dd>Contact
your healthcare provider right away as your medication needs may change.</dd>
</dl>
<ul class="Disc">
<li>Your healthcare provider should test your blood to measure how well
your kidneys are working before and during your treatment with ONGLYZA. You may need a lower dose of ONGLYZA if your kidneys are
not working well.</li>
<li>Follow your healthcare providerâ€™s instructions for treating blood
sugar that is too low (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>). Talk to your healthcare provider if
low blood sugar is a problem for you.</li>
<li>If you miss a dose of ONGLYZA, take it as soon as you remember.
If it is almost time for your next dose, skip the missed dose. Just take the
next dose at your regular time. Do not take two doses at the same time unless
your healthcare provider tells you to do so. Talk to your healthcare provider
if you have questions about a missed dose.</li>
<li>If you take too much ONGLYZA, call your healthcare provider or Poison
Control Center at 1-800-222-1222, or go to the nearest hospital emergency
room right away.</li>
</ul>
<p><span class="Bold">What
are the possible side effects of ONGLYZA?</span></p>
<p><span class="Bold">ONGLYZA can cause serious side effects, including:</span></p>
<ul class="Disc">
<li>See "<span class="Bold">What is the most important information I should know about ONGLYZA?</span>"</li>
<li>
<span class="Bold">Allergic (<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>) reactions</span>, such as:
							<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, lips, throat, and other areas on your skin</li>
<li>difficulty with swallowing or breathing</li>
<li>raised, red areas on your skin (<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, flaking, or <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span></li>
</ul>
</li>
</ul>
<dl class="Disc">
<dt>Â </dt>
<dd>If you have these symptoms, stop taking ONGLYZA and contact your healthcare provider right away.</dd>
</dl>
<p><span class="Bold">Common
side effects of ONGLYZA include:</span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span></li>
<li><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span></li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
</ul>
<p><span class="Bold">Low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>)</span> may become worse
in people who also take another medication to treat <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, such as sulfonylureas or insulin.
Tell your healthcare provider if you take other <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicines. If you
have symptoms of low blood sugar, you should check your blood sugar and treat
if low, then call your healthcare provider. Symptoms of low blood sugar include:
						</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span></li>
<li><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></li>
<li>rapid heartbeat</li>
<li>change in vision</li>
<li><span class="product-label-link" type="condition" conceptid="4205415" conceptname="Hungry">hunger</span></li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li>change in mood</li>
</ul>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span> or <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span></span> in your hands,
feet, or ankles (<span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>) may become worse in people who also take
a thiazolidinedione to treat <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. If you do not know whether you are
already on this type of medication, ask your healthcare provider.</p>
<p>These
are not all of the possible side effects of ONGLYZA. Tell your healthcare
provider if you have any side effects that bother you or that do not go away.
For more information, ask your healthcare provider.</p>
<p>Call
your healthcare provider for medical advice about side effects. You may report
side effects to the FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store ONGLYZA?</span></p>
<p>Store
ONGLYZA between 68Â°F and 77Â°F (20Â°C and 25Â°C).</p>
<p><span class="Bold">Keep
ONGLYZA and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the use of
ONGLYZA</span></p>
<p>Medicines are sometimes
prescribed for conditions that are not mentioned in Medication Guides. Do not
use ONGLYZA for a condition for which it was not prescribed. Do not give ONGLYZA
to other people, even if they have the same symptoms you have. It may harm
them.</p>
<p>This Medication Guide summarizes the most important
information about ONGLYZA. If you would like to know more information about
ONGLYZA, talk with your healthcare provider. You can ask your healthcare provider
for additional information about ONGLYZA that is written for healthcare professionals.
For more information, go to www.ONGLYZA.com or call 1-800-ONGLYZA.</p>
<p><span class="Bold">What are the ingredients of ONGLYZA?</span></p>
<p>Active
ingredient: saxagliptin</p>
<p>Inactive ingredients: lactose
monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium
stearate. In addition, the film coating contains the following inactive ingredients:
polyvinyl alcohol, polyethylene glycol, titanium dioxide, talc, and iron oxides.</p>
<p><span class="Bold">What is type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>?</span></p>
<p>Type
2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> is a condition in which your body does not make enough insulin,
and the insulin that your body produces does not work as well as it should.
Your body can also make too much sugar. When this happens, sugar (glucose)
builds up in the blood. This can lead to serious medical problems.</p>
<p>The
main goal of treating <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> is to lower your blood sugar so that it is as close to normal as possible.</p>
<p>High
blood sugar can be lowered by diet and exercise, and by certain medicines
when necessary.</p>
<br><br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="eSign2"></a><a name="section-18"></a><p></p>
<p class="First">This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p><br><br>ONGLYZA (saxagliptin) tablets<br><br>Manufactured by:<br>Bristol-Myers
Squibb Company<br> Princeton, NJ 08543 USA</p>
<p>Marketed
by:<br>Bristol-Myers Squibb Company<br> Princeton, NJ 08543<br>and<br>AstraZeneca
Pharmaceuticals LP<br>Wilmington, DE 19850</p>
<p>1297954 / 1256314A3 / 1296566A0<br>Rev December 2011</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s20"></a><a name="section-19"></a><p></p>
<p class="First"><span class="Bold">---------------------------------------------<br>REPRESENTATIVE PACKAGING</span></p>
<p>See 
							<span class="Bold">How Supplied</span> section for a complete list of available packages of ONGLYZA.
						</p>
<p>30 Tablets<br><br>ONGLYZA<span class="Sup">Â®</span><br>(saxagliptin) tablets<br>5 mg<br>DISPENSE WITH MEDICATION GUIDE<br>Rx only<br><img alt="Onglyza 5 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d45fc842-2563-4421-86af-a55b3191e19b&amp;name=6309.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ONGLYZAÂ 		
					</strong><br><span class="contentTableReg">saxagliptin tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6309(NDC:0003-4215)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>saxagliptin hydrochloride</strong> (saxagliptin) </td>
<td class="formItem">saxagliptin</td>
<td class="formItem">5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">5;4215</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-6309-0</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022350</td>
<td class="formItem">09/22/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7640cf93-5a17-4129-829b-f4a77bbda31e</div>
<div>Set id: d45fc842-2563-4421-86af-a55b3191e19b</div>
<div>Version: 3</div>
<div>Effective Time: 20120109</div>
</div>
</div>Â <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
